20220617-Mr G. H. Schorel-Hlavka O.W.B. To R Kershaw Chief Commissioner of The Australian Federal Police-Suppl 72-Legal Accountability Required

Page 1
1
2
3 Reece Kershaw (Australian date) 17-6-2022
4 Chief Commissioner of the Australian Federal Police
5 Forwarded via email commissioner@afp.gov.au
6
7 Cc: acv@health.gov.au Advisory Committee on Vaccines, Therapeutic Goods Administration
8 PO Box 100, WODEN ACT 2606 Attn: Pharmacovigilance and Special Access Branch, MDP 122
9 Committees@health.gov.au Committee Support Unit, Therapeutic Goods Administration
10 PO Box 100, WODEN ACT 2606 Attn: Scheduling & Committee Support Section, MDP 122
11
12 Mr Daniel Andrews Premier daniel.andrews@parliament.vic.gov.au
13 attorney-general@justice.vic.gov.au
14
15 Re: 20220617-Mr G. H. Schorel-Hlavka O.W.B. to R Kershaw Chief Commissioner of the Australian Federal Police-
16 Suppl 72-Legal accountability required
17
18 COMPLAINT
19 Sir,
20 further to my original COMPLAINT of 6 August 2021 I provide a further supplement hereby.
21
22 https://live.childrenshealthdefense.org/shows/good-morning-
23 chd?utm_source=salsa&utm_medium=email&utm_campaign=chd_tv&utm_term=chdtv&eType=EmailBlastConten
24 t&eId=dd25bb26-39cc-4461-a0d2-d6e23e25bc40
25
26 See also: https://live.childrenshealthdefense.org/shows/good-morning-chd/8iF-NcAVCl
27 JUNE 16, 2022GOOD MORNING CHD
17-6-2022 Page 1 © Mr G. H. Schorel-Hlavka O.W.B.
INSPECTOR-RIKATI® about the BLACK HOLE in the CONSTITUTION-DVD
A 1st edition limited special numbered book on Data DVD ISBN 978-0-9803712-6-0
PLEASE NOTE: You may order books in the INSPECTOR-RIKATI® series by making a reservation, or E-mail
admin@inspector-rikati.com See also www.scribd.com/inspectorrikati
Page 2
1 ‘Good Morning CHD’ Episode 53: 'My Son Mason Was Killed by Vaccines' — A Mother's
2 Warning
3 FDA Panel Recommends Moderna Two-Dose COVID Vaccine for Kids Ages 6 to 17
4 Despite Serious Safety Concerns: https://childrenshealthdefense.org/defender/fda-moderna-two-dose-
5 covid-vaccine-kids/?utm_source=salsa&eType=EmailBlastContent&eId=4f00dd67-0288-4285-870b-72b07ade66b4
6 Hands Off Our Children Campaign: https://childrenshealthdefense.org/community-
7 forum/tell-the-fda-hands-off-our-children/
8 WATCH VAXXED II: https://live.childrenshealthdefense.org/education/vaxxed2
9
10 https://live.childrenshealthdefense.org/shows/good-morning-
11 chd?utm_source=salsa&utm_medium=email&utm_campaign=chd_tv&utm_term=chdtv&eType
12 =EmailBlastContent&eId=dd25bb26-39cc-4461-a0d2-d6e23e25bc40
13
14
15 https://www.bitchute.com/video/7ttEVppkoyEG/
16
17 2090:53 Jun 08, 2022

18 Official Data Reveals Negative Protection From the Covid Vaccine - Dr. Paul Marik
19 “This consistent narrative of ‘safe + effective’ is a complete and utter lie.” — Official data
20 from the UK + Israel reveals negative protection from the COVID vaccine. Dr. Paul Marik on
21 #CHDTV
22 Watch FULL EPISODES of ‘Good Morning CHD’ on CHD.TV  Live Week Days 7am PT //
23 10pm ET ➡️ https://live.childrenshealthdefense.org/shows/good-morning-chd
24
25 Again:
26 “This consistent narrative of ‘safe + effective’ is a complete and utter lie.”
27
28 https://rumble.com/v18jfhw-i-never-had-a-single-unvaccinated-patient-with-autism-dr.-ben-tapper-on-
29 chd.html?utm_source=salsa&utm_medium=email&utm_campaign=chd_tv&utm_term=chd_tv&eType=EmailBlast
30 Content&eId=dd25bb26-39cc-4461-a0d2-d6e23e25bc40
31
32
33 "So Much Healthier" - Dr. Tapper's and Dr. Thomas' Experience With
34 Unvaccinated Children
35 Dr. Paul Thomas: How many kids in your unvaccinated population had autism or
36 other chronic conditions?
37 Dr. Ben Tapper: "I never had a single one have autism that was unvaccinated ...
38 they [moms with both vaccinated and unvaccinated kids] would tell you that
39 unvaccinated kids are healthier. They see it firsthand. They hit their milestones
40 sooner; they're speaking sooner. They're just healthier."

Page 3
1 WATCH THE FULL EPISODE ON #CHDTV

2 ⏯️ https://live.childrenshealthdefense.org/shows/against-the-wind-with-dr-paul-thomas
3 Special thanks to @TheVigilantFox for the clip!
4
5 https://rumble.com/v18gqa6-transgender-people-and-autism-behavior-analyst-explains-the-
6 connection-ask-.html
7 Transgender People & Autism: Behavior Analyst Explains The Connection – Ask Dr.
8 Drew
9 QUOTE
10 Dr. Drew Published June 14, 2022 9,894 Views
11 SUBSCRIBE121KJOINSHARE
12 Streamed on: Jun 14, 6:00 pm EDT
13 143 rumbles
14 EMBED
15 Enjoyed this video? Join my Locals community for exclusive content at drdrew.locals.com!
16 Recent studies have shown that people on the autism spectrum are more likely to identify as part
17 of the LGBTQ community – including some researchers who estimate that people with autism
18 traits are 2-3 times more likely to be transgender than those who are not on the spectrum.
19 Courtney Lasky is a Board Certified Behavior Analyst and a Director of Clinical Services with
20 BlueSprig Pediatrics. She is also a wife and mother of 6 children who has worked with autistic
21 individuals for over 15 years. She joins the show to discuss the research and offer tips on how to
22 support kids on the autism spectrum.
23 Find out more about Courtney Lasky and BlueSprig Pediatrics at https://BlueSprigAutism.com
24 END QUOTE
25 And
26 QUOTE
27 For over 30 years, Dr. Drew has answered questions and offered guidance to millions through
28 popular shows like Celebrity Rehab (VH1), Dr. Drew On Call (HLN), Teen Mom OG (MTV),
29 and the iconic radio show Loveline. Now, Dr. Drew is opening his phone lines to the world by
30 streaming LIVE from his home studio. Watch all of Dr. Drew's latest shows at https://drdrew.tv.
31 END QUOTE
32
33 QUOTE 20220616-Mr G. H. Schorel-Hlavka O.W.B. to Mr A. Albanese - Mask & vaccine craziness, etc
34 A. Albanese MP (Australian date) 16-6-2022
35 A.Albanese.MP@aph.gov.au & Portal
36
37 Cc: Prof Margaret Hellard doherty-reception@unimelb.edu.au
38
39 Prof Jodie McVernon doherty-reception@unimelb.edu.au
40
41
42 Re: 20220616-Mr G. H. Schorel-Hlavka O.W.B. to A. Albanese Mask &vaccination craziness
43 Sir,
44 I will commence with a real life example, which I view is relevant to my writings:
45
46 I was in management of factories when a 16 year young man came to my office and announced
47 that he had applied for a job but the Personal Manager had declined to give him a job. I was
48 impressed with his honesty and responded that I would put him through a test if he accepted that
49 and if he succeeded he had a job. He accepted. I asked him what his experiences were and he
50 explained he had been goat herding. As I was managing factories with expansive machinery I
51 obviously had to be very careful as to whom I would let operate such expensive machinery. I
52 asked him if he could show me on a ruler the length of “1 inch” he did. I announced he passed
53 the test and had a job. I asked him what his experiences were and he explained he had been goat
54 herding. As I was managing factories with expansive machinery

Page 4
1 That because he never had been involved in such work with machinery he then neither would
2 have bad habits and I would ensure he was given the best training to make him successful as the
3 fact that he was eager to work was the most important qualification. Within 6 months I had the
4 company to agree he would be paid adult wages, as I held he was equally if not better doing the
5 job than some setters who were 25 years or longer in the job. It was just natural to him to work
6 with expensive machinery, this should indicate that regardless if a person may not have the
7 qualifications in a particular profession never ignore the persons possibly ability.
8
9 I understand that Prof Margaret Hellard - "Pandemic Declaration Accountability and Oversight
10 Committee" & Prof Jodie McVernon -Doherty Institute mention of the "National Cabinet" are
11 making recommendations, etc, as to mask, social distancing, lockdowns, curfews, QR code, etc. I
12 have no scientific or medical education and so perhaps now like the goat herder position.
13
14 If I were to go to a bank manager and request to withdraw $100,000 it would be reasonably to
15 expect the bank manager would decline this if I cannot prove to have even a bank account with
16 the bank let alone any monies and neither an estate worthy as guarantee. Likewise, I would pose
17 the question to anyone, and so also to Prof Margaret Hellard & Prof Jodie McVernon can
18 either and/or both produce to me evidence that SARS-CoV-2 was isolated and purified by the
19 Koch postulates? Surely this should not be difficult to prove where both seems to me having
20 been advising upon the existence of SARS-CoV-2 virus? We obviously do not want to crap of
21 the modelling by Neil Fergusson of the UK where the modelling was not at all designed upon
22 SARS-CoV-2 virus existing but merely assumed!
23
24 My blog at https://www.scribd.com/inspectorrikati has ample of information published on it
25 including that on 6 August 2021I filed a COMPLAINT with the Australian Federal Police with
26 so far 71 supplements totalling some 2,845 pages already and more to come, that I view that
27 politicians, scientist, health officials, and others all should be held legally accountable for the
28 spread of their disinformation, etc, and causing untold harm and death to many Australians.
29
30 Olga, my wife, berated me during our marriage that I was ignorant to medical issues. I simply
31 had no interest in it. That all changed on 10 October 2019 when I rushed her to hospital and the
32 doctor gave me the understanding that Had I not done so Olga would be likely been death within
33 hours due to heart failure, etc. when then the claims about COVID started I decided to research
34 as after all albeit Olga is 89 I still like to spend many years with her company. So, I commenced
35 to research and research and quickly became aware how there was this rot to deny normal
36 communication about the pro’s and con’s alleged about being jabbed.
37 Experts whom warned about the dangers were becoming outcast and the Big Tech began to deny
38 proper publications.
39 I wondered why on earth would for example the Chief Health Officer from Queensland request
40 Big Tech to deny publications that were contrary to the government’s claims. Surely “science” is
41 not static and can be reviewed over time when for whatever reasons details/information comes to
42 be known that never before had been considered? When anyone seeks to mute the views of
43 others then I view this is done for unethical reasons and more over a denial of a person’s
44 constitutional rights.
45
46 Despite all the fear mongering I did not use any mask in 2020, 2021 and 2022. On 10 august
47 2020 the Victorian Police made known they would summons me to court for not wearing a mask
48 and I responded I was ready for this. Well the summons never came.
49 I was on 28 August 2020 assaulted by a man about 1/3 my age also about not wearing a mask but
50 it didn’t alter my position. Despite the supermarket making clear they had the assault on video,
51 the Victorian Police claimed no video existed. It really was to me that the Victorian Police was
Page 5
1 more like terrorist to attack anyone not joining the COVOD death cult than to uphold the rule of
2 law. Ample of videos have been published on the internet how the police has acted like thugs
3 rather than law enforcement officers.
4
5 As I have made clear that the states do not have any constitutional legislative, executive and
6 administrative powers regarding “man-kind” (infectious) diseases and as such any advice to the
7 Victorian Government by any professional as to mandates would be ride on a train in Antarctica.
8
9 In my view any advice by Prof Margaret Hellard and/or Prof Jodie McVernon to the
10 Victorian Government regarding any kind of mandate would be baloney where constitutionally
11 the State of Victoria lacks any power to legislate, to govern and/or to administrate any “man-
12 kind” infectious disease.
13
14 https://expose-news.com/2022/06/02/when-we-know-what-propaganda-is-will-we-be-free/
15 QUOTE
16 Meanwhile, with millions now fixated on that raging “anti-fascist” propaganda drive (whether
17 they believed it, or resisted it), Year Two of the Covid crisis started with the rollout of the most
18 fascistic “Covid measure” of them all — the long-awaited “vaccination” program, which Bill
19 Gates, in a televised exchange with Stephen Colbert, had hyped, indiscreetly, as “the Final
20 Solution.”
21 END QUOTE
22 And
23 QUOTE
24 Thus, throughout 2020 — Year One of the now-endless Covid crisis — we were inescapably
25 suffused with terror of “the virus,” and thereby bullied into locking down (despite the scientific
26 fact that lockdowns do more harm than good), while also masking all the time, and
27 everywhere, and “social-distancing” as well (despite the scientific fact that neither practice
28 “slows the spread” of any respiratory virus). While masking was imposed, ostensibly, to make
29 us less afraid of Covid-19, it only made us more afraid of one another, and so compounded
30 that disabling fear with a ferocious anger at all those not wearing masks (despite the scientific
31 fact that masks would not prevent transmission of “the virus” even if the entire global
32 population wore them all the time).
33 END QUOTE
34 And
35 QUOTE
36 This means, first of all, doing what the “fact-checkers” claim to do, and doing it far more
37 conscientiously, and thoroughly, than they “debunk” whatever facts or theories contradict, or
38 complicate, the narrative pumped out by governments and media. Whereas the “fact-
39 checkers” do quick and sloppy work, and then move on, we work in depth, in scholarly
40 commitment to the truth, which may take decades to discover — as with JFK’s murder, and
41 the other key assassinations at that time, and 9/11; and just as we persist in careful refutation
42 of the propaganda still obscuring those historic crimes, and others, so, throughout these last
43 two years, have we been digging for, and trying to tell, the widely buried truth about the Covid
44 crisis, its true origins, the actual lethality of SARS-CoV-2 (whatever that may really be), the
45 PCR tests used to measure “cases,” the “Covid measures” hatched (allegedly) to “slow the
46 spread,” the absolute futility of lockdowns, and their catastrophic harms, the homicidal impact
47 of the standard Covid “treatment,” and the actual availability of valid remedies, the cynical
48 redefinition of such key terms as “pandemic,” “cases,” “herd immunity,” “vaccine” and, “fully
49 vaccinated,” the likely motives driving this whole crisis (and those still to com e), the actual low
50 number of those killed worldwide by Covid, and — above all — the ever-growing global toll of
51 the experimental “vaccination” program; and now that Covid, and its “variants,” and
52 “vaccination” have been pushed out of the spotlight by “Ukraine” (though governments-and-
53 media continue warning us hysterically of “Covid” and its “variants,” and shouting at us to “get
54 vaccinated”), we strive to find, and tell, the buried truths about that conflict — how and why it
55 started, how it’s being fought on either side, and the fact that dozens of “atrocities” ascribed to
56 Russia have turned out to be as bogus as those crimes charged to “the Hun” in World War
Page 6
1 One, the Iraqi army in Kuwait in 1990, and Bashar al-Assad, president of Syria, from 2011 until
2 his imaginary barbarism was eclipsed by “the coronavirus,” and then Putin’s barbarism in
3 Ukraine.
4 END QUOTE
5
6 https://www.globalresearch.ca/what-we-learned-from-hating-unvaccinated/5781072?pdf=5781072
7 What We Learned from Hating the Unvaccinated
8 QUOTE
9 The battlefield is still warm, following Canada’s war on the unvaccinated. The mandates have
10 let up, and both sides stumble back into something that looks like the old normal — except that
11 there is a fresh and present injury done to the people we tried to break. And no one wants to
12 talk about it.
13 Only weeks ago, it was the admitted goal of our own leaders to make life unlivable for
14 the unvaccinated. And as a deputized collective, we force-multiplied that pain, taking
15 the fight into our families, friendships, and workplaces. Today, we face the hard truth
16 that none of it was justified — and, in doing that, uncover a precious lesson.
17 It was a quick slide from righteousness to cruelty, and however much we might blame
18 our leaders for the push, we’re accountable for stepping into the trap despite better
19 judgement.
20 We knew that waning immunity put vast numbers of the fully vaccinated on par with
21 the shrinking minority of unvaccinated, yet we marked them for special persecution.
22 We said they hadn’t “done the right thing” by turning their bodies over to state care —
23 even though we knew that principled opposition to such a thing is priceless in any
24 circumstance. And we truly let ourselves believe that going into another ineffectual
25 lockdown would be their fault, not the fault of toxic policy.
26 Video: “You all will have implants.” – Klaus Schwab and Google Co-Founder
27 Look Ahead to Transhumanism
28 And so it was by the wilful ignorance of science, civics, and politics that we squeezed
29 the unvaccinated to the degree that we did.
30 We invented a new rubric for the good citizen and — failing to be one ourselves —
31 took pleasure in scapegoating anyone who didn’t measure up. After months of
32 engineered lockdowns, having someone to blame and to burn simply felt good.
33 So we cannot hold our heads high, as if believing we had logic, love, or truth on our
34 side while we viciously wished death upon the unvaccinated. The best we can do is sit
35 in the awareness of our rabid inhumanity for having cast so many aside.
36 Most of us who pilloried the noncompliant did it because it seemed like certain victory,
37 like the unvaccinated would never make it through unbroken. Indeed, the promised
38 new normal looked unbeatable, so we sided with it and made punching bags out of
39 the holdouts.
40 But betting against them has been a scathing embarrassment for many of us who’ve
41 now learned that the mandates only had the power we gave them. It was not through
42 quiet compliance that we avoided endless domination by pharmaceutical companies

Page 7
1 and medical checkpoints at every doorway. It was thanks to the people we tried to tear
2 down.
3 So for those of us not among the hopeless few that pray for the return of mandates,
4 we might find some inner gratitude for the unvaccinated. We took the bait by hating
5 them, but their perseverance bought us the time to see we were wrong.
6 It seems right now like the mandates will return, but this time there’s hope that more of
7 us will see them for what they are: a rising authoritarianism that has no concern for
8 our wellbeing. If there’s an enemy, it’s the confidence game of state power and the
9 transparent attempt to tear us apart. Heeding that looks like our best shot at
10 redemption.
11 END QUOTE
12
13 Email received:
14 QUOTE
15 Death by Doctors
16 Yahoo/Inbox
17 Carol P <prendyspot@gmail.com>
18 To:undisclosed-recipients:;
19 Bcc:inspector_rikati@yahoo.com.au
20 Fri, 3 June at 2:03 pm
21 I heard today that 24 people in a retirement village in my area all died after the booster !! There will
22 be so many deaths and grief this Winter, from the covid jabs, yet the muppets keep lining up to get
23 it, even the 'free' flu shot, gosh isn't it generous of the health dept to give out this poison ?
24 No mention of boosting your immune system with large doses of Vit C, zinc, Vit D3, sunshine &
25 fresh air, as well as daily fresh fruit & veges. People that die are labelled as Covid victims, what a
26 load of BS, it's death & harm by death jabs from doctors who have sold their soul to Big Pharma.
27 Legalised genocide.
28
29 The agenda is clear for those that have eyes to see & ears to hear, it's not hard to join the dots.
30 There will always be those that continue to wear a face muzzle & do as they're told from
31 unauthorised officials, like good programmed sheeple. How many more ambos have you heard, or
32 seen more funerals, how many have you heard that's died recently ?
33
34 Of course the Govt is responsible for mandates, un necessary lockdowns, destroying the economy
35 and killing the population, put them in jail or hang as traitors. But no they won't be liable for any of
36 it, nothing to see here, move on.
37
38 Most of the people I know understand the satanic Agenda.
39 More & more are waking up, but sadly it's too late for the thousands that will die.
40 Bring on a Royal Commission and Class Action
41 --
Page 8
1 Cheers
2 Carol
3
4 END QUOTE
5
6 https://www.theepochtimes.com/may-the-force-be-with-them-scientists-fight-
7 back_4502259.html?utm_source=healthnoe&utm_campaign=health-2022-06-
8 04&utm_medium=email&est=0YP%2F6xTH1DaBp%2BdnMda84d4xNWJDRCOZdmCftkx3F
9 cJUniJJMiZFnxaE7XNwEXEehWT6XvsW7mMm
10 QUOTE
11 Three months later, an editorial was published in the April edition of Surgical
12 Neurology International: “COVID UPDATE: What is the truth?” by retired
13 neurosurgeon Dr. Russell L. Blaylock. Blaylock was frank and direct in his
14 condemnation of the public health policies implemented to contain COVID-19.
15 Indeed, he unapologetically calls the pandemic “one of the most manipulated
16 infectious disease events in history, characterized by official lies in an
17 unending stream lead by government bureaucracies, medical associations,
18 medical boards, the media, and international agencies.”
19 END QUOTE
20 And
21 QUOTE
22 Government-imposed lockdowns, vaccine mandates, keeping people in fear,
23 and silencing scientific debate have all garnered approval from the global
24 scientific community.
25 But for those of us who noticed that the public health information being
26 disseminated often contradicted itself, it seemed that Dark Forces had been in
27 control.
28 Silence and Censorship Make Bad Science
29 Some of us have known all along that the public health agenda of advancing
30 pharmaceutical talking points, disseminating fear, and insisting that only a for-
31 profit, rushed to market vaccine would not stop COVID.
32 Others of us are just waking up to the inconvenient truth that the entire
33 pandemic response may have been wrong and that our blind obedience and
34 trust in authority were misguided.
35 No matter what your beliefs are about COVID, vaccines, lockdowns, social
36 distancing, masking, and school closures, however, it’s important to understand
37 that the only way out of the collective mess humanity is in right now is to be
38 willing to disagree, talk honestly, and encourage the process of scientific inquiry.

Page 9
1 Yet since the beginning of the COVID crisis, when honest scientists, professors,
2 and medical doctors began to speak up, they were, and continue to be, silenced,
3 canceled, de-platformed, and defamed.
4 Even now, “science” has become so politicized that doctors willing to speak
5 truth to power have lost their jobs, their social standing, and their licenses to
6 practice medicine.
7
8 END QUOTE
9 And
10 QUOTE
11 Indeed, he unapologetically calls the pandemic “one of the most manipulated
12 infectious disease events in history, characterized by official lies in an
13 unending stream lead by government bureaucracies, medical associations,
14 medical boards, the media, and international agencies.”
15 END QUOTE
16
17 https://rwmalonemd.substack.com/p/tyranny-of-the-modelers?s=r
18 Tyranny of the Modelers
19 QUOTE
20 There are so very many factors that have contributed to the clear and compelling reality
21 that the public health response to the global SARS-CoV-2 outbreak has been one of the
22 greatest failures in public policy in modern history. But chief among those has been the
23 grossly overestimated modeling projections of likely disease and death due to the virus.
24 Those well versed in the world of computer software coding are intimately familiar with
25 the problem of “Garbage in - Garbage out” (GIGO), which is short slang for the real world
26 issue that the utility of any coded data set analysis is a function of the quality of the
27 underlying data being analyzed and the assumptions engineered into the computer code. In
28 retrospect, it is abundantly clear that the underlying data and assumptions which were used
29 to develop the modeling which formed the basis for global public health policy decisions
30 concerning the management of the outbreak were seriously flawed. These flawed analyses,
31 which were promoted via a wide range of government policy analysis and media channels,
32 almost universally wildly over-estimated the risks of the virus.
33 END QUOTE
34
35 https://www.theepochtimes.com/researcher-we-made-a-big-mistake-on-covid-19-
36 vaccine_4469331.html?utm_source=ai_recommender
37 QUOTE
38 Standard studies designed to assess these risks were not performed in compliance with
39 accepted empirical research standards. Furthermore, in key studies designed to test
40 whether the vaccine remains near the injection site or travels throughout the body,
Page 10
1 Pfizer did not even use the commercial vaccine (BNT162b2) but instead relied on a
2 ‘surrogate’ mRNA producing the luciferase protein.
3 END QUOTE
4
5 https://childrenshealthdefense.org/defender/covid-vaccines-incurable-fatal-degenerative-
6 brain-disorder/?utm_source=salsa&eType=EmailBlastContent&eId=9c2f0145-8a41-435d-
7 9771-58ad9acdec2e
8 COVID Vaccines Linked to New Type of Incurable, Fatal Degenerative Brain
9 Disorder
10
11
12 https://rumble.com/vc5pt8-today-they-were-forced-to-admit-that-covid-19-does-not-
13 exist.html
14 TODAY THEY WERE FORCED TO ADMIT THAT 'COVID-19' DOES NOT EXIST
15
16
17 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062939/#__ffn_sectitle
18 COVID UPDATE: What is the truth?
19 QUOTE
20 The COVID-19 pandemic is one of the most manipulated infectious disease

21 events in history, characterized by official lies in an unending stream lead by
22 government bureaucracies, medical associations, medical boards, the media,
23 and international agencies.[3,6,57] We have witnessed a long list of
24 unprecedented intrusions into medical practice, including attacks on medical
25 experts, destruction of medical careers among doctors refusing to participate
26 in killing their patients and a massive regimentation of health care, led by
27 non-qualified individuals with enormous wealth, power and influence.
28 For the first time in American history a president, governors, mayors, hospital
29 administrators and federal bureaucrats are determining medical treatments
30 based not on accurate scientifically based or even experience based
31 information, but rather to force the acceptance of special forms of care and
32 “prevention”—including remdesivir, use of respirators and ultimately a series
33 of essentially untested messenger RNA vaccines. For the first time in history
34 medical treatment, protocols are not being formulated based on the experience
35 of the physicians treating the largest number of patients successfully, but
36 rather individuals and bureaucracies that have never treated a single patient—
37 including Anthony Fauci, Bill Gates, EcoHealth Alliance, the CDC, WHO,
38 state public health officers and hospital administrators.[23,38]
39 The media (TV, newspapers, magazines, etc), medical societies, state medical
40 boards and the owners of social media have appointed themselves to be the
41 sole source of information concerning this so-called “pandemic”. Websites
42 have been removed, highly credentialed and experienced clinical doctors and
43 scientific experts in the field of infectious diseases have been demonized,
Page 11
1 careers have been destroyed and all dissenting information has been labeled
2 “misinformation” and “dangerous lies”, even when sourced from top experts
3 in the fields of virology, infectious diseases, pulmonary critical care, and
4 epidemiology. These blackouts of truth occur even when this information is
5 backed by extensive scientific citations from some of the most qualified
6 medical specialists in the world.[23] Incredibly, even individuals, such as Dr.
7 Michael Yeadon, a retired ex-Chief Scientist, and vice-president for the
8 science division of Pfizer Pharmaceutical company in the UK, who charged
9 the company with making an extremely dangerous vaccine, is ignored and
10 demonized. Further, he, along with other highly qualified scientists have
11 stated that no one should take this vaccine.
12 Dr. Peter McCullough, one of the most cited experts in his field, who has
13 successfully treated over 2000 COVID patients by using a protocol of early
14 treatment (which the so-called experts completely ignored), has been the
15 victim of a particularly vicious assault by those benefiting financially from
16 the vaccines. He has published his results in peer reviewed journals, reporting
17 an 80% reduction in hospitalizations and a 75% reduction in deaths by using
18 early treatment.[44] Despite this, he is under an unrelenting series of attacks
19 by the information controllers, none of which have treated a single patient.
20 Neither Anthony Fauci, the CDC, WHO nor any medical governmental
21 establishment has ever offered any early treatment other than Tylenol,
22 hydration and call an ambulance once you have difficulty breathing. This is
23 unprecedented in the entire history of medical care as early treatment of
24 infections is critical to saving lives and preventing severe complications. Not
25 only have these medical organizations and federal lapdogs not even suggested
26 early treatment, they attacked anyone who attempted to initiate such treatment
27 with all the weapons at their disposal—loss of license, removal of hospital
28 privileges, shaming, destruction of reputations and even arrest.[2]
29 A good example of this outrage against freedom of speech and providing

30 informed consent information is the recent suspension by the medical board in
31 Maine of Dr. Meryl Nass’ medical license and the ordering of her to undergo
32 a psychiatric evaluation for prescribing Ivermectin and sharing her expertise
33 in this field.[9,65] I know Dr, Nass personally and can vouch for her integrity,
34 brilliance and dedication to truth. Her scientific credentials are impeccable.
35 This behavior by a medical licensing board is reminiscent of the methodology
36 of the Soviet KGB during the period when dissidents were incarcerated in
37 psychiatric gulags to silence their dissent.
38 END QUOTE
39

Page 12
1 https://www.globalresearch.ca/covid-
2 lies/5778646?utm_campaign=magnet&utm_source=article_page&utm_medium=related_articles
3 The COVID Lies
4 QUOTE
5 Given the foregoing, it is no longer possible to view the last two years as well- intentioned errors.
6 Instead, the objectives of the perpetrators are most likely to be totalitarian control over the
7 population by means of mandatory digital IDs and cashless central bank digital currencies (CBDCs).
8 In the first part of the article (The Covid Lies), Dr. Yeadon counters the 12 widespread
9 Covid narratives with the following arguments:
10 1. The infection fatality rate of SARS-CoV-2 is 0.1 – 0.3%, which is not significantly
11 different from some seasonal influenza epidemics.
12 2. Based on the peer-reviewed articles, at least 30 to 50% of the population has prior
13 cross-immunity.
14 3. SARS-CoV-2 does discriminate. “The lethality of this virus, as is common with respiratory
15 viruses, is 1000X less in young, healthy people than in elderly people with multiple
16 comorbidities.”
17 4. Asymptomatic transmission is the “central conceptual deceit” used to “underscore
18 almost every intrusion: masking, mass testing, lockdowns, border restrictions, school closures,
19 even vaccine passports.”
20 5. PCR test is “the central operational deceit.”
21 6. Neither cloth nor surgical masks prevent respiratory virus transmission.
22 7. Lockdown is “epidemiologically irrelevant” and never works. “Only “stay home if you’re
23 sick” works.“
24 8. “Covid-19 is the most treatable respiratory viral illness ever”. Safe and effective early
25 treatments are available.
26 9. Based on the peer-reviewed articles, very few clinically significant reinfections of
27 SARS-Cov-2 have ever been confirmed.
28 10. SARS-CoV-2 mutates slowly, and no variant is even close to escaping naturally-
29 acquired immunity. However, there is the possibility that the so-called vaccines
30 prevent the establishment of immune memory, leading to the repeated infections,
31 which would be a form of acquired immune deficiency.
32 11. Safety is the top priority in a public health mass intervention, even more than
33 effectiveness. “It was NEVER appropriate to attempt to “end the pandemic” with a novel
34 technology vaccine.”
35 12. The four gene-based “vaccines” are toxic. The basic rules of selecting vaccine
36 candidates are: 1) the agent has no inherent biological action (non-toxic); 2) the agent
37 should be the genetically most stable part of the virus; 3) the agent should be most
38 different from human proteins. Spike protein as the vaccine does not fit any of the
39 above criteria.
40 In the second part of the article (How Much of the Covid-19 Narrative Was True? Additional
41 Reflections), Dr. Yeadon further stresses his contention on the Covid-19 narratives on:
42 Dr. Peter McCullough: COVID Jab Death Count ‘Is Worse Than a War’
43  Unprecedented Pronouncements by the senior scientific and medical advisers, such
44 as “Everyone is vulnerable.”
45  Instigating Fear
46  Using Mass Testing to Promote Fear
Page 13
1  One Dominant Narrative

2  More Vaccine Lies
3  The Question of Motive
4 At the end of the article, Dr. Yeadon also provides a list of extra supplemental points to
5 support his conclusions.
6 Click here to read the full document.

7 END QUOTE
8
9 https://www.globalresearch.ca/covid-update-what-
10 truth/5779037?utm_campaign=magnet&utm_source=article_page&utm_medium=related_articles
11 The COVID Pandemic and the mRNA Vaccine: What Is the Truth? Dr. Russell L.
12 Blaylock
13 QUOTE
14 It has never been tested for effects on a long list of medical conditions:
15  Diabetes
16  Heart disease
17  Atherosclerosis
18  Neurodegenerative diseases
19  Neuropsychiatric effects
20  Induction of autism spectrum disorders and schizophrenia
21  Long term immune function
22  Vertical transmission of defects and disorders
23  Cancer
24  Autoimmune disorders
25 Previous experience with the flu vaccines clearly demonstrates that the safety
26 studies done by researchers and clinical doctors with ties to pharmaceutical
27 companies were essentially all either poorly done or purposefully designed to falsely
28 show safety and coverup side effects and complications. This was dramatically
29 demonstrated with the previously mentioned phony studies designed to indicate that
30 hydroxy Chloroquine and Ivermectin were ineffective and too dangerous to use.[34 ,
31 36 , 37] These fake studies resulted in millions of deaths and severe health disasters
32 worldwide. As stated, 80% of all deaths were unnecessary and could have been
33 prevented with inexpensive, safe repurposed medications with a very long safety
34 history among millions who have taken them for decades or even a lifetime.[43 , 44]
35 END QUOTE
36
37 https://www.globalresearch.ca/now-crucial-understand-what-were-up-against/5783281
38 It’s Now Crucial to Understand What We’re Up Against.

39 The COVID Pandemic is A Coup d’état, A Global Takeover
40 Referred to as “The Great Reset”
41
42 https://www.globalresearch.ca/pseudopandemic/5768536?utm_campaign=magnet&utm_source=
43 article_page&utm_medium=related_articles

Page 14
1 Covid-19 Is a “Pseudopandemic”
2
3 https://www.theepochtimes.com/the-war-against-the-unvaxxed-will-not-be-
4 forgotten_4514945.html?utm_source=healthnoe&utm_campaign=health-2022-06-
5 14&utm_medium=email&est=Q0yVJRUU8Ti7NT77W7%2Fd3O1OPVpPoQ9Pdkk6EGQ
6 2J7Gv84LZ%2BqN0ggRyfG%2F4Ru71d%2FfLSEcCIq%2BU
7 The War Against the Unvaxxed Will Not Be Forgotten
8
9 https://www.globalresearch.ca/video-effort-to-stop-the-vaccine-and-prosecute-the-perpetrators-
10 the-case-of-lawyer-philip-
11 hyland/5783109?utm_campaign=magnet&utm_source=article_page&utm_medium=related_artic
12 les
13 Video: Effort to Stop the Vaccine and Prosecute the

14 Perpetrators. The Case of Lawyer Philip Hyland and the
15 London Metropolitan Police Inquiry
16 Criminal complaint of Gross Negligence Manslaughter and

17 Misconduct in Public Office.
18
19 https://www.naturalnews.com/2022-06-09-pfizer-documents-mrna-covid-vaccines-mass-
20 depopulation.html
21 BOMBSHELL: Pfizer’s own documents

22 admit that mRNA covid vaccines will
23 result in mass depopulation
24 QUOTE
25 Of 270 tracked pregnancies, Pfizer lost track of 238 of
26 them
27 The latest batch of released Pfizer documents also contains a concerning
28 revelation about pregnancies of which the company somehow lost track. Of the
29 270 pregnancies Pfizer was tracking, a shocking 238 of them just disappeared
30 from the dataset.
31 Of the 33 pregnancies that Pfizer still tracked, a shocking 23 of them
32 resulted in spontaneous abortion. Two resulted in premature baby death;
33 two resulted in intrauterine death; one resulted in neonatal death; one is
34 listed as “outcome pending;” and only one resulted in a “normal outcome.”
35 END QUOTE
36
Page 15
1 I for one cannot accept that considering the many stages or reporting and as such on computer
2 records than somehow 238 in totality are missing.
3
4
5
6
7 https://articles.mercola.com/sites/articles/archive/2022/06/09/scientism.aspx?ui=2452e48ee850e
8 01d1c6738932cddb7dcaf9043a15984f355d7aa522cd46b564a&sd=20201124&cid_source=dnl&
9 cid_medium=email&cid_content=art1ReadMore&cid=20220609&mid=DM1186806&rid=1514
10 930390
11 Scientism, Not Science, Rules the Roost
12 QUOTE
13 STORY AT-A-GLANCE
14  As technocracy and transhumanism have risen to the fore, they have brought with
15 them their own form of science — “scientism” — which is basically the religion of
16 science. In other words, it’s a belief even in the absence of evidence, or in the face of
17 contrary evidence, and this is a very serious problem
18  The clearest problem with the admonition to “believe the science” is that bona fide
19 experts are found on all sides of any given empirical question
20  The scientific priesthood is intolerant to new ideas while, simultaneously, search

21 engines and digitization of scientific literature have eroded their authority as
22 gatekeepers of knowledge
23  The way things look right now, the gatekeepers to the scientific priesthood don’t
24 seem to have any intention to open its doors to outsiders and independent thinkers.
25 If anything, they’re trying to massively increase their control over the information
26 we’re allowed to see and share, even to the point of proposing the creation of
27 certifying boards to police physicians’ sharing of medical opinions
28  The idea that a group of people can be the sole arbiters of “truth” is irrational.
29 Individual biases always creep in, and the greater the influence of such a group, the
30 more ingrained and dogmatic those biases will become, until the system is corrupted
31 to the core. One could argue that dogmatic faith in nonexistent scientific
32 consensuses is the reason for why we are where we are today
33 END QUOTE
34
35 https://www.drpaulalexander.com/blogs/news/the-dangers-of-masks
36 The Dangers of Masks
37 QUOTE
38 by Paul Alexander
39 November 11, 2021
40 This is a public health warning to the US population and elsewhere, as it appears that our
41 public health agencies and television medical experts seem unable to address key health
42 messages that could have a dramatic effect in reducing risk of severe sequelae in higher-
43 risk populations such as the minority and African-American population to the scourge of
44 SARS-CoV-2. This is now clear. They have squandered many an opportunity to inform the
45 public on simple yet very effective messaging that could reduce morbidity and save lives.
46 Not just for Covid-19, but our focus here is on Covid-19.

Page 16
1 For example, obesity has emerged as a potent human target for the SARS-CoV-2 in most
2 studies, in addition to being elderly, frail and having comorbid conditions. It would
3 behoove our agencies to address these risks in a large-scale education program for the
4 populace and especially by calling for a reduction in body weight and particularly for the
5 minority sub-groups (African-Americans). In a similar light, studies have shown
6 that vitamin D supplementation for African-Americans has been associated with a lowered
7 risk of severe disease and mortality from the SARS-CoV-2.
8 Early ambulatory outpatient treatment with successful combination and sequenced antiviral
9 agents, corticosteroids, and anti-clotting therapeutics should be used widely to help the
10 people at risk. The African-American community is aware that, “Covid (is) a killer for the
11 obese: like pouring gasoline on top of a fire.” Unfortunately, more than a year into the
12 pandemic, the manifest issue of public health education and sound policy decisions remain
13 aloof, given the erratic and confusing responses from the health and governing officials.
14 We are calling for an aggressive focus on our minority populations (and all of our
15 population), as they are usually overlooked and disregarded by public health leaders and
16 agencies. We plead for effective and needed public health messaging.
17 With that clarion call, we pivot and refer here to another looming concern and this is the
18 potential danger of the chlorine, polyester, and microplastic components of the face masks
19 (surgical principally but any of the mass-produced masks) that have become part of our
20 daily lives due to the Covid-19 pandemic. We hope those with persuasive power in the
21 government will listen to this plea. We hope that the necessary decisions will be made to
22 reduce the risk to our populations.
23 Emergent reports, albeit nascent and anecdotal but nevertheless vitally important (and will
24 be clarified and defined in time) regarding the manufacture of masks, where, “many of
25 them (face masks) are made of polyester, so you have a microplastic problem…many of
26 the face masks would contain polyester with chlorine compounds…if I have the mask in
27 front of my face, then of course I inhale the microplastic directly and these substances are
28 much more toxic than if you swallow them, as they get directly into the nervous system.”
29 There are also reports of toxic mould, fungi, and bacteria that can pose a significant threat
30 to the immune system by potentially weakening it. Of particular concern to us is the recent
31 report of breathing in synthetic fibers in the face masks. This is of serious concern. “Loose
32 particulate was seen on each type of mask. Also, tight and loose fibers were seen on each
33 type of mask. If every foreign particle and every fiber in every facemask is always secure
34 and not detachable by airflow, then there should be no risk of inhalation of such particles
35 and fibers. However, if even a small portion of mask fibers is detachable by inspiratory
36 airflow, or if there is debris in mask manufacture or packaging or handling, then there is
37 the possibility of not only entry of foreign material to the airways, but also entry to deep
38 lung tissue, and potential pathological consequences of foreign bodies in the lungs.”
39 Reports are that “Graphene is a strong, very thin material that is used in fabrication, but it
40 can be harmful to lungs when inhaled and can cause long-term health problems.” We argue
41 that there is a risk of potential ‘future’ inflammatory/fibrotic lung diseases because we are
42 inhaling these materials in the masks now for over one year with more duration to come
43 and no end in sight. These substances might also be highly carcinogenic. Not just for us as
Page 17
1 adults but we must be very concerned about the risks especially to our children since they
2 depend on us as mentors and guides for their decision-making. It is our children that we are
3 very concerned for.
4 These blue surgical masks pervade our lives. “Health Canada has issued a
5 warning about blue and gray disposable face masks, which contain an asbestos-like
6 substance associated with “early pulmonary toxicity.” The warning is specific to
7 potentially toxic masks distributed within schools and daycares across Quebec. Health
8 Canada (and full praise to them)….“discovered during a preliminary risk assessment that
9 the masks contain microscopic graphene particles that, when inhaled, could cause severe
10 lung damage.”
11 Reports are that “for a while now, some daycare educators had expressed suspicion about
12 the masks, which were causing children to feel as though they were swallowing cat hair
13 while wearing them. We now know that instead of cat hair, children were inhaling the
14 equivalent of asbestos all day long.”.It appears to be a substance known as graphene. What
15 is indeed alarming is that “the SNN200642 masks that were being used all across Canada
16 in school classrooms had never been tested for safety or effectiveness.” This is indeed a
17 catastrophic failure by the regulators as these surgical face masks are linked to early
18 pulmonary toxicity.
19 What is indeed frightening is that all of these blue and similar surgical face masks
20 cause plastic fiber inhalation and the outcomes could be devastating, especially to our
21 children. These plastics will degrade very slowly over time and as such, in the lungs it may
22 remain and just build up to dangerous levels. We do not even know what is an ‘acceptable’
23 level, for there should be none, zero! There is debate that the immune system can attack
24 such foreign objects, thus driving prolonged inflammation which may lead to diseases such
25 as cancer. And reused masks which pervade our daily lives, and based on our personal
26 experiences, do produce more loosened fibers. Dr. Richard Urso showed us just how
27 dangerous these are by putting them under a microscope, revealing the melt-blown
28 polypropylene plastic. Some masks even contain fiberglass and this is very dangerous as
29 we know to inhale. We as parents make these decisions, we have to step back and question
30 many of these decisions we are making that seem suboptimal. If it does not seem right,
31 then you have to push back and question and demand the science, demand the data from
32 these seemingly untethered experts.
33 We certainly are not getting the due diligence and protection from public health experts,
34 the relevant health agencies, and policy makers that we need. They are failing us! Covid-19
35 has crystallized this. The government leaders are quick to tell us that they are relying on
36 the advice of these experts in their advisory groups who seem incapable of reading the
37 science or are just blinded to it. It is an academic sloppiness and cognitive dissonance that
38 is terrifying by these experts should they come upon anything that differs from their beliefs
39 or views, even when they are clearly wrong!
40 Moreover, the mass media seems incapable of doing the investigative type of journalism to
41 fully inform the populace on what the public needs to know. We close by reiterating the
42 warning in the JAMA publication that “Face masks should not be worn by healthy
43 individuals to protect themselves from acquiring respiratory infection because there is no
Page 18
1 evidence to suggest that face masks worn by healthy individuals are effective in preventing
2 people from becoming ill.” We raise this issue of potential harm due to synthetic fibres,
3 chlorine, and chemicals from Covid masks as a public health warning and call on the
4 public to make its own relevant risk-management decisions, weighing the benefits versus
5 the harms (downsides) of such a course of action. Especially with the surgical masks (blue)
6 or similar that quickly get moisture laden with use, fibers tend to get loose and may enter
7 the mouth and nose.
8 Every act has a consequence, and there is always risk. It is therefore imperative to weigh
9 the consequences before embarking on a specific course of action. These are risk
10 management decisions especially for parents and not because a Dr. Fauci type tells you to
11 do something means that it is accurate or necessary. Just consider the nonsense we heard
12 about double masking where he said use them one day only to then retract on another day.
13 We just saw the bizarre and troubling change by the CDC that social distancing for kids no
14 longer required 6 feet and now can be 3 feet but not when in the company of teachers.
15 Outrageous is the fact that the 6-feet rule was arbitrary and based on no underpinning
16 science in the first place. It’s as if the virus floats around and makes these distance
17 adjustments.
18 What about when one day the CDC Director says vaccinated persons do not carry the virus
19 to then reverse the next day? Even Dr. Fauci went against the CDC. So who is telling the
20 nation the truth on any given matter? What are we to believe? We are told you should
21 vaccinate with a vaccine that does not have the requisite safety assessment (another serious
22 matter that is being swept aside), and then you still must wear a mask and socially distance.
23 It makes no sense.
24 It is all nonsensical, illogical, specious, and patently absurd some of what these agencies
25 and experts spew to us all day long. Many of it is just plain wrong. We urge you to think
26 this through carefully. Any available evidence must be considered when the health of the
27 citizenry is at stake. Minor risks can turn into major disasters, like cracks in a dam.
28 We caution you on the safety of these face masks especially since the science also has
29 revealed the ineffectiveness of mask mandates and the masks themselves, as currently
30 used. We are parents and citizens alike, and you and we only seek to inform, share,
31 prognosticate. You must be informed fully for informed decision-making. We also cannot
32 discount the possible harms on our immune systems and general health from such constant
33 and prolonged use of masks, given that we have never done this before.
34 We are in uncharted territory and especially so with the possible implications for our
35 children. Their immune systems are still being developed and we are forcing lockdowns,
36 school closures, and masking on a developing child and we have no prior experience on the
37 subsequent outcomes pertaining to children’s development, health, and well-being. These
38 are matters too important to nonchalantly disregard. The consequences could be
39 catastrophic and lifelong, especially for our children.

Page 19
1 Contributing Authors
2  Paul E Alexander MSc PhD, McMaster University and GUIDE Research Methods
3 Group, Hamilton, Ontario, Canada elias98_99@yahoo.com
4  Howard C. Tenenbaum DDS, Dip. Perio., PhD, FRCD(C) Centre for Advanced Dental
5 Research and Care, Mount Sinai Hospital, and Faculties of Medicine and Dentistry,
6 University of Toronto, Toronto, ON, Canada howard.tenenbaum@sinaihealth.ca
7  Dr. Parvez Dara, MD, MBA, daraparvez@gmail.com

8 Published by the American Institute for Economic Research
9 https://www.aier.org/article/the-dangers-of-masks/
10
11 END QUOTE
12
13 https://www.globalresearch.ca/covid-19-vaccines-scientific-proof-
14 lethality/5767711?utm_campaign=magnet&utm_source=article_page&utm_medium=related_art
15 icles
16 COVID-19 Vaccines: Proof of Lethality. Over One Thousand Scientific Studies
17 QUOTE
18 Over One Thousand Scientific Studies Prove That the COVID-19 Vaccines Are Dangerous,
19 and All Those Pushing This Agenda Are Committing the Indictable Crime of Gross
20 Misconduct in Public Office
21 Just over 12 months from deployment of the COVID 19 emergency use experimental
22 vaccines, scientific studies in the thousands, and reports of criminal complaints of
23 assault and murder from the illegal, unlawful use of biochemical poisons made to
24 police forces around the country, verify an assault on an unsuspecting UK population.
25 Irrefutable science shows that the COVID 19 vaccine is not safe and not effective in
26 limiting transmission or infection from the SARS-CoV-2, coronavirus pathogens.
27 The “safe and effective” false propaganda, put out by public officials who now are
28 continuing to push this vaccine, is a clear breach of duty. A public office holder is
29 subject to, and aware of, a duty to prevent death or serious injury that arises only by
30 virtue of the functions of the public office.
31 Many have breached that duty and, in doing so, are recklessly causing a risk of death
32 or serious injury, by carrying on regardless of the now-confirmed dangers associated
33 with COVID 19 injections. Some of these risks are blood clotting, myocarditis,
34 pericarditis, thrombosis, thrombocytopenia, anaphylaxis, Bell’s palsy, Guillain-Barre,
35 cancer including deaths, etc.
36 All of these are confirmed in the following science-and-government-gathered data from
37 the UK Health and Security agency on COVID 19 regarding vaccine damage.
38 The term “vaccine” was changed recently to incorporate this illegal, unlawful medical
39 experiment to facilitate usage of mRNA technology that is demonstrably not a vaccine,
40 and which contains biologically toxic nano-metamaterials associated with 5G urban
41 data gathering capability.
42 Metal nanoparticulates are known in science to be genotoxic—a poison that can also
43 cause sterilization. The dangers posed to the victims in the near term from this
44 medical battery are now known. However, the long term lethality of this weapon is not

Page 20
1 as yet realized due to the debilitating effects it has on the immune system, causing
2 Acquired Immunodeficiency Syndrome(AIDS).
3 We can now confirm the 2017 depopulation defence-intelligence documents, showing

4 the planned murder of over 55 million across the United Kingdom by 2025 using this
5 biochemical weapon.
6 The Medicines and Healthcare (products) Regulatory Agency (MHRA) had prior
7 warning of the expected large numbers of adverse reactions before the deployment—
8 confirming the premeditated nature of the crime and public conduct offences then and
9 now.
10 1. Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre

11 cohort study: https://www.thelancet.com/journals/lancet/article/PIIS0140-
12 6736(21)01608-1/
13 2. Vaccine-induced immune thrombotic thrombocytopenia with disseminated
14 intravascular coagulation and death after ChAdOx1 nCoV-19
15 vaccination: https://www.sciencedirect.com/science/article/pii/S1052305721003414
16 3. Fatal cerebral hemorrhage after COVID-19
17 vaccine: https://pubmed.ncbi.nlm.nih.gov/33928772/
18 4. Myocarditis after mRNA vaccination against SARS-CoV-2, a case
19 series: https://www.sciencedirect.com/science/article/pii/S2666602221000409
20 5. Three cases of acute venous thromboembolism in women after vaccination against
21 COVID-19: https://www.sciencedirect.com/science/article/pii/S2213333X21003929
22 6. Acute thrombosis of the coronary tree after vaccination against COVID-
23 19: https://www.sciencedirect.com/science/article/abs/pii/S1936879821003988
24 7. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after
25 vaccination with Ad26.COV2.S (against covid-19), March 2 to April 21,
26 2020: https://pubmed.ncbi.nlm.nih.gov/33929487/
27 8. Portal vein thrombosis associated with ChAdOx1 nCov-19
28 vaccine: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00197-
29 7/
30 9. Management of cerebral and splanchnic vein thrombosis associated with
31 thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca):
32 position statement of the Italian Society for the Study of Hemostasis and Thrombosis
33 (SISET): https://pubmed.ncbi.nlm.nih.gov/33871350/
34 10. Vaccine-induced immune immune thrombotic thrombocytopenia and cerebral
35 venous sinus thrombosis after vaccination with COVID-19; a systematic
36 review: https://www.sciencedirect.com/science/article/pii/S0022510X21003014
37 11. Thrombosis with thrombocytopenia syndrome associated with COVID-19
38 vaccines: https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381
39 12. Covid-19 vaccine-induced thrombosis and thrombocytopenia: a commentary on an
40 important and practical clinical
41 dilemma: https://www.sciencedirect.com/science/article/abs/pii/S0033062021000505
42 13. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector

Page 21
1 14. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an

2 emerging cause of splanchnic vein
3 thrombosis: https://www.sciencedirect.com/science/article/pii/S1665268121000557
4 15. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced
5 immune thrombotic immune thrombocytopenia
6 (covid): https://www.sciencedirect.com/science/article/pii/S1050173821000967
7 16. Roots of autoimmunity of thrombotic events after COVID-19
8 vaccination: https://www.sciencedirect.com/science/article/abs/pii/S156899722100216
9 0
10 17. Cerebral venous sinus thrombosis after vaccination: the United Kingdom
11 experience: https://www.thelancet.com/journals/lancet/article/PIIS0140-
12 6736(21)01788-8/fulltext
13 18. Thrombotic immune thrombocytopenia induced by SARS-CoV-2
14 vaccine: https://www.nejm.org/doi/full/10.1056/nejme2106315
15 19. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the
16 US military. This article reports that in “23 male patients, including 22 previously
17 healthy military members, myocarditis was identified within 4 days after receipt of the
18 vaccine”: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601
19 20. Thrombosis and thrombocytopenia after vaccination with ChAdOx1 nCoV-
20 19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104882?query=recirc_curatedRela
21 ted_article
22 21. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine
23 in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
24 22. Thrombotic thrombocytopenia after vaccination with ChAdOx1 nCov-
25 19: https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRela
26 ted_article
27 23. Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (covid-
28 19): https://haematologica.org/article/view/haematol.2021.279075
29 24. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19
30 mRNA vaccines reported to the Vaccine Adverse Event Reporting System
31 (VAERS): https://www.sciencedirect.com/science/article/pii/S0264410X21005247
32 25. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-
33 19
34 vaccination: https://pediatrics.aappublications.org/content/early/2021/06/04/peds.2021
35 -052478
36 26. Aphasia seven days after the second dose of an mRNA-based SARS-CoV-2
37 vaccine. Brain MRI revealed an intracerebral hemorrhage (ICBH) in the left temporal
38 lobe in a 52-year-old
39 man. https://www.sciencedirect.com/science/article/pii/S2589238X21000292#f0005
40 27. Comparison of vaccine-induced thrombotic episodes between ChAdOx1 nCoV-19
41 and Ad26.COV.2.S
43 28. Hypothesis behind the very rare cases of thrombosis with thrombocytopenia
44 syndrome after SARS-CoV-2
45 vaccination: https://www.sciencedirect.com/science/article/abs/pii/S004938482100331
46 5

Page 22
1 29. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19
2 vaccination: analysis of European
3 data: https://www.sciencedirect.com/science/article/pii/S0896841121000937
4 30. Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2
5 vaccine: https://www.sciencedirect.com/science/article/abs/pii/S1052305721003098
6 31. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia
7 induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine
8 (VITT): https://www.sciencedirect.com/science/article/pii/S0953620521002363
9 32. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical
10 considerations for care
11 providers: https://www.sciencedirect.com/science/article/pii/S0828282X21006243
12 33. “Portal vein thrombosis occurring after the first dose of SARS-CoV-2 mRNA vaccine
13 in a patient with antiphospholipid
14 syndrome”: https://www.sciencedirect.com/science/article/pii/S2666572721000389
15 34. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral
16 venous sinus thrombosis after vaccination with
17 Ad26.COV2.S: https://www.sciencedirect.com/science/article/pii/S0196064421003425
18 35. Myocarditis, pericarditis and cardiomyopathy after COVID-19
20 36. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia
21 (VITT) compared to natural SARS-CoV-2
22 infection: https://www.sciencedirect.com/science/article/abs/pii/S0896841121000706
23 37. Prothrombotic immune thrombocytopenia after COVID-19
25 38. Vaccine-induced thrombotic thrombocytopenia: the dark chapter of a success
26 story: https://www.sciencedirect.com/science/article/pii/S2589936821000256
27 39. Cerebral venous sinus thrombosis negative for anti-PF4 antibody without
28 thrombocytopenia after immunization with COVID-19 vaccine in a non-comorbid
29 elderly Indian male treated with conventional heparin-warfarin based
30 anticoagulation: https://www.sciencedirect.com/science/article/pii/S187140212100204
31 6
32 40. Thrombosis after COVID-19 vaccination: possible link to ACE
33 pathways: https://www.sciencedirect.com/science/article/pii/S0049384821004369
34 41. Cerebral venous sinus thrombosis in the U.S. population after SARS-CoV-2
35 vaccination with adenovirus and after COVID-
36 19: https://www.sciencedirect.com/science/article/pii/S0735109721051949
37 42. A rare case of a middle-aged Asian male with cerebral venous thrombosis after
38 AstraZeneca COVID-19
40 43. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19
41 vaccination: report of two cases in the United
42 Kingdom: https://www.sciencedirect.com/science/article/abs/pii/S088915912100163X
43 44. Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine
44 (ChAdOx1 nCov-
45 19): https://www.sciencedirect.com/science/article/abs/pii/S0006497121013963.
46 45. Antiphospholipid antibodies and risk of thrombophilia after COVID-19 vaccination:
47 the straw that breaks the camel’s
Page 23
1 back?: https://docs.google.com/document/d/1XzajasO8VMMnC3CdxSBKks1o7kiOLX
2 FQ
3 46. Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire
4 in the battle against the COVID-19 pandemic: What
5 pathogenesis?: https://www.sciencedirect.com/science/article/pii/S095362052100231
6 4
7 47. Diagnostic-therapeutic recommendations of the ad-hoc FACME expert working
8 group on the management of cerebral venous thrombosis related to COVID-19
10 48. Thrombocytopenia and intracranial venous sinus thrombosis after exposure to the
11 “AstraZeneca COVID-19 vaccine”: https://pubmed.ncbi.nlm.nih.gov/33918932/
12 49. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2
13 vaccination: https://pubmed.ncbi.nlm.nih.gov/33606296/
14 50. Severe and refractory immune thrombocytopenia occurring after SARS-CoV-2
16 51. Purpuric rash and thrombocytopenia after mRNA-1273 (Modern) COVID-19
17 vaccine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996471/
18 52. COVID-19 vaccination: information on the occurrence of arterial and venous
19 thrombosis using data from VigiBase: https://pubmed.ncbi.nlm.nih.gov/33863748/
20 53. Cerebral venous thrombosis associated with the covid-19 vaccine in
21 Germany: https://onlinelibrary.wiley.com/doi/10.1002/ana.26172
22 54. Cerebral venous thrombosis following BNT162b2 mRNA vaccination of BNT162b2
23 against SARS-CoV-2: a black swan event: https://pubmed.ncbi.nlm.nih.gov/34133027/
24 55. The importance of recognizing cerebral venous thrombosis following anti-COVID-19
26 56. Thrombosis with thrombocytopenia after messenger RNA vaccine -
28 57. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an
29 analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
30 58. First dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic,
31 thromboembolic, and hemorrhagic events in
32 Scotland: https://www.nature.com/articles/s41591-021-01408-4
33 59. Exacerbation of immune thrombocytopenia after COVID-19
35 60. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based
36 anti-COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105244/
37 61. PF4 immunoassays in vaccine-induced thrombotic
38 thrombocytopenia: https://www.nejm.org/doi/full/10.1056/NEJMc2106383
39 62. Antibody epitopes in vaccine-induced immune immune thrombotic
40 thrombocytopenia: https://www.nature.com/articles/s41586-021-03744-4
41 63. Myocarditis with COVID-19 mRNA
42 vaccines: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.05613
43 5
44 64. Myocarditis and pericarditis after COVID-19
45 vaccination: https://jamanetwork.com/journals/jama/fullarticle/2782900

Page 24
1 65. Myocarditis temporally associated with COVID-19

2 vaccination: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.055
3 891.
4 66. COVID-19 Vaccination Associated with Myocarditis in
5 Adolescents: https://pediatrics.aappublications.org/content/pediatrics/early/2021/08/12
6 /peds.2021-053427.full.pdf
7 67. Acute myocarditis after administration of BNT162b2 vaccine against COVID-
9 68. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute
10 myocarditis: case report and review of the
11 literature: https://www.sciencedirect.com/science/article/pii/S1553838921005789
12 69. COVID-19 vaccine-induced myocarditis: a case report with review of the
14 70. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR
15 findings: https://www.sciencedirect.com/science/article/pii/S1936878X2100485X
16 71. Recurrence of acute myocarditis temporally associated with receipt of coronavirus
17 mRNA disease vaccine 2019 (COVID-19) in a male
18 adolescent: https://www.sciencedirect.com/science/article/pii/S002234762100617X
19 72. Fulminant myocarditis and systemic hyper inflammation temporally associated with
20 BNT162b2 COVID-19 mRNA vaccination in two
21 patients: https://www.sciencedirect.com/science/article/pii/S0167527321012286.
22 73. Acute myocarditis after administration of BNT162b2
23 vaccine: https://www.sciencedirect.com/science/article/pii/S2214250921001530
24 74. Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral
25 vector: https://www.sciencedirect.com/science/article/pii/S2352906721001573
26 75. Myocarditis following vaccination with BNT162b2 in a healthy
27 male: https://www.sciencedirect.com/science/article/pii/S0735675721005362
28 76. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with
29 previous SARS-CoV-2
30 infection: https://www.sciencedirect.com/science/article/pii/S1930043321005549
31 77. Myopericarditis after Pfizer mRNA COVID-19 vaccination in
32 adolescents: https://www.sciencedirect.com/science/article/pii/S002234762100665X
33 78. Pericarditis after administration of BNT162b2 mRNA COVID-19 mRNA
35 79. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273
36 mRNA: https://www.sciencedirect.com/science/article/pii/S2589790X21001931
37 80. Temporal relationship between the second dose of BNT162b2 mRNA Covid-19
38 vaccine and cardiac involvement in a patient with previous SARS-COV-2
39 infection: https://www.sciencedirect.com/science/article/pii/S2352906721000622
40 81. Myopericarditis after vaccination with COVID-19 mRNA in adolescents 12 to 18
41 years of age: https://www.sciencedirect.com/science/article/pii/S0022347621007368
42 82. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old
43 man: https://www.sciencedirect.com/science/article/pii/S0870255121003243
44 83. Important information on myopericarditis after vaccination with Pfizer COVID-19
45 mRNA in
46 adolescents: https://www.sciencedirect.com/science/article/pii/S0022347621007496

Page 25
1 84. A series of patients with myocarditis after vaccination against SARS-CoV-2 with
2 mRNA-1279 and
3 BNT162b2: https://www.sciencedirect.com/science/article/pii/S1936878X21004861
4 85. Takotsubo cardiomyopathy after vaccination with mRNA COVID-
5 19: https://www.sciencedirect.com/science/article/pii/S1443950621011331
6 86. COVID-19 mRNA vaccination and
7 myocarditis: https://pubmed.ncbi.nlm.nih.gov/34268277/
8 87. COVID-19 vaccine and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34399967/
9 88. Epidemiology and clinical features of myocarditis/pericarditis before the introduction
10 of COVID-19 mRNA vaccine in Korean children: a multicenter
11 study https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-
12 ncov/resourc e/en/covidwho-1360706.
13 89. COVID-19 vaccines and myocarditis: https://pubmed.ncbi.nlm.nih.gov/34246566/
14 90. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based
15 COVID-19 vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-
16 cardiovascular-comp lications-of-the-mrna-based-covid-19-
17 vaccines https://www.cureus.com/articles/61030-myocarditis-and-other-
18 cardiovascular-complications-of-the-mrna-based-covid-19-vaccines
19 91. Myocarditis, pericarditis, and cardiomyopathy after COVID-19
21 92. Myocarditis with covid-19 mRNA
22 vaccines: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056135
23 93. Association of myocarditis with COVID-19 mRNA vaccine in
24 children: https://media.jamanetwork.com/news-item/association-of-myocarditis-with-
25 mrna-co vid-19-vaccine-in-children/
26 94. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a
27 case series of
28 children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
29 95. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the
30 U.S. military: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601%5C
31 96. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19
32 vaccines: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600
33 97. Myocarditis following immunization with Covid-19
34 mRNA: https://www.nejm.org/doi/full/10.1056/NEJMc2109975
35 98. Patients with acute myocarditis after vaccination withCOVID-19
36 mRNA: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602
37 99. Myocarditis associated with vaccination with COVID-19
38 mRNA: https://pubs.rsna.org/doi/10.1148/radiol.2021211430
39 100. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19
40 Vaccination: https://pediatrics.aappublications.org/content/148/3/e2021052478
41 101. Cardiovascular magnetic resonance imaging findings in young adult patients with
42 acute myocarditis after COVID-19 mRNA vaccination: a case series: https://jcmr-
43 online.biomedcentral.com/articles/10.1186/s12968-021-00795-4
44 102. Clinical Guidance for Young People with Myocarditis and Pericarditis after
45 Vaccination with COVID-19 mRNA: https://www.cps.ca/en/documents/position/clinical-
46 guidance-for-youth-with-myocarditis-and-pericarditis

Page 26
1 103. Cardiac imaging of acute myocarditis after vaccination with COVID-19

2 mRNA: https://pubmed.ncbi.nlm.nih.gov/34402228/
3 104. Case report: acute myocarditis after second dose of mRNA-1273 SARS-CoV-2
4 mRNA vaccine: https://academic.oup.com/ehjcr/article/5/8/ytab319/6339567
5 105. Myocarditis / pericarditis associated with COVID-19
6 vaccine: https://science.gc.ca/eic/site/063.nsf/eng/h_98291.html
7 106. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19
8 vaccine: https://journals.lww.com/pidj/Abstract/9000/Transient_Cardiac_Injury_in_Adol
9 esce nts_Receiving.95800.aspx
10 107. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19
11 vaccine: https://academic.oup.com/jpids/advance-
12 article/doi/10.1093/jpids/piab060/6329543
13 108. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible
14 underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/
15 109. Acute myocardial injury after COVID-19 vaccination: a case report and review of
16 current evidence from the Vaccine Adverse Event Reporting System
17 database: https://pubmed.ncbi.nlm.nih.gov/34219532/
18 110. Be alert to the risk of adverse cardiovascular events after COVID-19
19 vaccination: https://www.xiahepublishing.com/m/2472-0712/ERHM-2021-00033
20 111. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac
21 tomography, and magnetic resonance imaging
22 findings: https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.121.013236
23 112. In-depth evaluation of a case of presumed myocarditis after the second dose of
24 COVID-19 mRNA
25 vaccine: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056038
26 113. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an
27 accidental coincidence or rather a vaccination-associated autoimmune
28 myocarditis?: https://pubmed.ncbi.nlm.nih.gov/34333695/
29 114. Recurrence of acute myocarditis temporally associated with receipt of coronavirus
30 mRNA disease vaccine 2019 (COVID-19) in a male
31 adolescent: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216855/
32 115. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced
33 reaction?: https://pubmed.ncbi.nlm.nih.gov/34118375/
34 116. Self-limited myocarditis presenting with chest pain and ST-segment elevation in
35 adolescents after vaccination with the BNT162b2 mRNA
37 117. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination:
38 Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
39 118. Biopsy-proven lymphocytic myocarditis after first COVID-19 mRNA vaccination in a
40 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
41 119. Insights from a murine model of COVID-19 mRNA vaccine-induced myopericarditis:
42 could accidental intravenous injection of a vaccine induce
43 myopericarditis https://academic.oup.com/cid/advance-
44 article/doi/10.1093/cid/ciab741/6359059
45 120. Unusual presentation of acute perimyocarditis after modern SARS-COV-2 mRNA-
46 1237 vaccination: https://pubmed.ncbi.nlm.nih.gov/34447639/

Page 27
1 121. Perimyocarditis after the first dose of mRNA-1273 SARS-CoV-2 (Modern) mRNA-
2 1273 vaccine in a young healthy male: case
3 report: https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-021-
4 02183
5 122. Acute myocarditis after the second dose of SARS-CoV-2 vaccine: serendipity or
6 causal relationship: https://pubmed.ncbi.nlm.nih.gov/34236331/
7 123. Rhabdomyolysis and fasciitis induced by the COVID-19 mRNA
9 124. COVID-19 vaccine-induced rhabdomyolysis: case report with literature
10 review: https://pubmed.ncbi.nlm.nih.gov/34186348/.
11 125. GM1 ganglioside antibody and COVID-19-related Guillain Barre syndrome: case
12 report, systemic review, and implications for vaccine
13 development: https://www.sciencedirect.com/science/article/pii/S2666354621000065
14 126. Guillain-Barré syndrome after AstraZeneca COVID-19 vaccination: causal or casual
15 association: https://www.sciencedirect.com/science/article/pii/S0303846721004169
16 127. Sensory Guillain-Barré syndrome after ChAdOx1 nCov-19 vaccine: report of two
17 cases and review of the
19 128. Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine: a temporary
20 occurrence, not a causal
21 association: https://www.sciencedirect.com/science/article/pii/S2214250921000998.
22 129. Guillain-Barré syndrome presenting as facial diplegia after vaccination with COVID-
23 19: a case
24 report: https://www.sciencedirect.com/science/article/pii/S0736467921006442
25 130. Guillain-Barré syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first
26 report: https://www.sciencedirect.com/science/article/pii/S0035378721005853.
27 131. SARS-CoV-2 vaccines are not safe for those with Guillain-Barre syndrome following
29 132. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic
30 response to methylprednisolone: a case
32 133. Facial nerve palsy following administration of COVID-19 mRNA vaccines: analysis of
33 self-report
34 database: https://www.sciencedirect.com/science/article/pii/S1201971221007049
35 134. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine:
36 cause or
37 coincidence: https://www.sciencedirect.com/science/article/pii/S0899707121003557.
38 135. New-onset refractory status epilepticus after ChAdOx1 nCoV-19
40 136. Acute myelitis and ChAdOx1 nCoV-19 vaccine: coincidental or causal
41 association: https://www.sciencedirect.com/science/article/pii/S0165572821002137
42 137. Bell’s palsy and SARS-CoV-2 vaccines: an unfolding
43 story: https://www.sciencedirect.com/science/article/pii/S1473309921002735
44 138. Bell’s palsy after the second dose of the Pfizer COVID-19 vaccine in a patient with a
45 history of recurrent Bell’s
46 palsy: https://www.sciencedirect.com/science/article/pii/S266635462100020X

Page 28
1 139. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA
2 vaccine:. https://www.sciencedirect.com/science/article/pii/S2451993621001456.
3 140. Bell’s palsy after COVID-19 vaccination: case
4 report: https://www.sciencedirect.com/science/article/pii/S217358082100122X.
5 141. An academic hospital experience assessing the risk of COVID-19 mRNA vaccine
6 using patient’s allergy
7 history: https://www.sciencedirect.com/science/article/pii/S2213219821007972
8 142. COVID-19 vaccine-induced axillary and pectoral lymphadenopathy in
9 PET: https://www.sciencedirect.com/science/article/pii/S1930043321002612
10 143. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19
12 144. Late cutaneous reactions after administration of COVID-19 mRNA
13 vaccines: https://www.sciencedirect.com/science/article/pii/S2213219821007996
14 145. COVID-19 vaccine-induced rhabdomyolysis: case report with review of the
16 146. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including
17 V-REPP: a registry-based
18 study: https://www.sciencedirect.com/science/article/pii/S0190962221024427
19 147. Thrombosis with thrombocytopenia syndrome associated with COVID-19
20 vaccines:. https://www.sciencedirect.com/science/article/abs/pii/S0735675721004381.
21 148. COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis
22 Committee of the World Allergy
23 Organization:. https://www.sciencedirect.com/science/article/pii/S1939455121000119.
25 thrombocytopenia after immunization with COVID-19 vaccine in an elderly, non-
26 comorbid Indian male treated with conventional heparin-warfarin-based
27 anticoagulation:. https://www.sciencedirect.com/science/article/pii/S187140212100204
28 6.
30 19:. https://www.sciencedirect.com/science/article/abs/pii/S188558572100133X
31 151. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccine: an
32 analysis of European
33 data:. https://www.sciencedirect.com/science/article/pii/S0896841121000937.
34 152. immune thrombocytopenia associated with Pfizer-BioNTech’s COVID-19 BNT162b2
35 mRNA
36 vaccine:. https://www.sciencedirect.com/science/article/pii/S2214250921002018.
37 153. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Moderna)
38 vaccine: Case
39 report: https://www.sciencedirect.com/science/article/pii/S1876034121001878.
40 154. COVID-19 RNA-based vaccines and the risk of prion disease:
41 https://scivisionpub.com/pdfs/covid19rna-based-vaccines-and-the-risk-of-prion-dis
42 ease-1503.pdf
43 155. This study notes that 115 pregnant women lost their babies, out of 827 who
44 participated in a study on the safety of covid-19
45 vaccines: https://www.nejm.org/doi/full/10.1056/NEJMoa2104983.
46 156. Process-related impurities in the ChAdOx1 nCov-19
47 vaccine: https://www.researchsquare.com/article/rs-477964/v1
Page 29
1 157. COVID-19 mRNA vaccine causing CNS inflammation: a case

2 series: https://link.springer.com/article/10.1007/s00415-021-10780-7
3 158. Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-
4 BioNTech COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33475702/
5 159. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene
6 glycol: https://pubmed.ncbi.nlm.nih.gov/33320974/
7 160. Pfizer Vaccine Raises Allergy Concerns: https://pubmed.ncbi.nlm.nih.gov/33384356/
8 161. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-
9 BioNTech COVID-19 vaccine – United States, December 14-23,
11 162. Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-
12 19 vaccine – United States, December 21, 2020-January 10,
14 163. Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea,
15 February 26-April 30, 2021: https://pubmed.ncbi.nlm.nih.gov/34414880/
16 164. Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec
17 14, 2020-Jan 18, 2021: https://pubmed.ncbi.nlm.nih.gov/33576785/
18 165. Immunization practices and risk of anaphylaxis: a current, comprehensive update of
19 COVID-19 vaccination data: https://pubmed.ncbi.nlm.nih.gov/34269740/
20 166. Relationship between pre-existing allergies and anaphylactic reactions following
21 administration of COVID-19 mRNA
23 167. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy
24 Research: https://pubmed.ncbi.nlm.nih.gov/33932618/
25 168. Severe Allergic Reactions after COVID-19 Vaccination with the Pfizer / BioNTech
26 Vaccine in Great Britain and the USA: Position Statement of the German Allergy
27 Societies: German Medical Association of Allergologists (AeDA), German Society for
28 Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology
29 and Environmental Medicine (GPA): https://pubmed.ncbi.nlm.nih.gov/33643776/
30 169. Allergic reactions and anaphylaxis to LNP-based COVID-19
31 vaccines: https://pubmed.ncbi.nlm.nih.gov/33571463/
32 170. Reported orofacial adverse effects from COVID-19 vaccines: the known and the
33 unknown: https://pubmed.ncbi.nlm.nih.gov/33527524/
34 171. Cutaneous adverse effects of available COVID-19
36 172. Cumulative adverse event report of anaphylaxis following injections of COVID-19
37 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month
38 report: https://pubmed.ncbi.nlm.nih.gov/34347278/
39 173. COVID-19 vaccines increase the risk of
40 anaphylaxis: https://pubmed.ncbi.nlm.nih.gov/33685103/
41 174. Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-
42 19 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
43 175. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible
44 involvement of polyethylene glycol and IgG-mediated complement
45 activation: https://pubmed.ncbi.nlm.nih.gov/33657648/
46 176. Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA
47 COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33825239/
Page 30
1 177. Acute allergic reactions to COVID-19 mRNA

3 178. Polyethylene glycole allergy of the SARS CoV2 vaccine recipient: case report of a
4 young adult recipient and management of future exposure to SARS-
5 CoV2: https://pubmed.ncbi.nlm.nih.gov/33919151/
6 179. Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine
7 against COVID-19 in Japanese healthcare workers; a secondary analysis of initial
8 post-approval safety data: https://pubmed.ncbi.nlm.nih.gov/34128049/
9 180. Allergic reactions and adverse events associated with administration of mRNA-
10 based vaccines. A health system
11 experience: https://pubmed.ncbi.nlm.nih.gov/34474708/
12 181. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society of Allergy
13 and Clinical Immunology
14 (BelSACI): https://www.tandfonline.com/doi/abs/10.1080/17843286.2021.1909447
15 182. .IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to
16 COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34318537/
17 183. Allergic reactions after COVID-19 vaccination: putting the risk in
18 perspective: https://pubmed.ncbi.nlm.nih.gov/34463751/
19 184. Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further studies:
20 https://pubmed.ncbi.nlm.nih.gov/33846043/ 188.
21 185. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic
22 skin disease: practical recommendations. An ETFAD position statement with external
23 experts: https://pubmed.ncbi.nlm.nih.gov/33752263/
24 186. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility
25 diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
26 187. Fatal brain hemorrhage after COVID-19
28 188. A case series of skin reactions to COVID-19 vaccine in the Department of
29 Dermatology at Loma Linda University: https://pubmed.ncbi.nlm.nih.gov/34423106/
30 189. Skin reactions reported after Moderna and Pfizer’s COVID-19 vaccination: a study
31 based on a registry of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/
32 190. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including
33 V-REPP: a registry-based study: https://pubmed.ncbi.nlm.nih.gov/34517079/
34 191. Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-
35 sectional study of 405 cases: https://pubmed.ncbi.nlm.nih.gov/34254291/
36 192. Varicella zoster virus and herpes simplex virus reactivation after vaccination with
37 COVID-19: review of 40 cases in an international dermatologic
38 registry: https://pubmed.ncbi.nlm.nih.gov/34487581/
39 193. Immune thrombosis and thrombocytopenia (VITT) associated with the COVID-19
40 vaccine: diagnostic and therapeutic recommendations for a new
41 syndrome: https://pubmed.ncbi.nlm.nih.gov/33987882/
42 194. Laboratory testing for suspicion of COVID-19 vaccine-induced thrombotic (immune)
43 thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34138513/
44 195. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after
45 COVID-19 vaccination: the first fatal case in
46 Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/

Page 31
1 196. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and

2 positive SARS-CoV-2 tests: self-controlled case series
3 study: https://pubmed.ncbi.nlm.nih.gov/34446426/
4 197. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus
5 thrombosis after covid-19 vaccination; a systematic
6 review: https://pubmed.ncbi.nlm.nih.gov/34365148/.
7 198. Nerve and muscle adverse events after vaccination with COVID-19: a systematic
8 review and meta-analysis of clinical trials: https://pubmed.ncbi.nlm.nih.gov/34452064/.
9 199. A rare case of cerebral venous thrombosis and disseminated intravascular
10 coagulation temporally associated with administration of COVID-19
12 200. Primary adrenal insufficiency associated with thrombotic immune thrombocytopenia
13 induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine
14 (VITT): https://pubmed.ncbi.nlm.nih.gov/34256983/
15 201. Acute cerebral venous thrombosis and pulmonary artery embolism associated with
16 the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
17 202. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after
18 administration of AstraZeneca COVID-19
20 203. 59-year-old woman with extensive deep venous thrombosis and pulmonary
21 thromboembolism 7 days after a first dose of Pfizer-BioNTech BNT162b2 mRNA
22 vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34117206/
23 204. Cerebral venous thrombosis and vaccine-induced thrombocytopenia.a. Oxford-
24 AstraZeneca COVID-19: a missed opportunity for a rapid return on
26 205. Myocarditis and other cardiovascular complications of mRNA-based COVID-19
28 206. Pericarditis after administration of COVID-19 mRNA BNT162b2
30 207. Unusual presentation of acute pericarditis after vaccination against SARS-COV-2
31 mRNA-1237 Modern: https://pubmed.ncbi.nlm.nih.gov/34447639/
32 208. Case report: acute myocarditis after second dose of SARS-CoV-2 mRNA-1273
33 vaccine mRNA-1273: https://pubmed.ncbi.nlm.nih.gov/34514306/
34 209. Immune-mediated disease outbreaks or recent-onset disease in 27 subjects after
35 mRNA/DNA vaccination against SARS-CoV-
37 210. Insights from a murine model of myopericarditis induced by COVID-19 mRNA
38 vaccine: could accidental intravenous injection of a vaccine induce
39 myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34453510/
40 211. Immune thrombocytopenia in a 22-year-old post Covid-19
42 212. propylthiouracil-induced neutrophil anti-cytoplasmic antibody-associated vasculitis
43 after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34451967/
44 213. Secondary immune thrombocytopenia (ITP) associated with ChAdOx1 Covid-19
45 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34377889/

Page 32
1 214. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca

2 ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination: risk-benefit analysis for
3 persons <60 years in Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
4 215. COVID-19 vaccination association and facial nerve palsy: A case-control
6 216. The association between COVID-19 vaccination and Bell’s
7 palsy: https://pubmed.ncbi.nlm.nih.gov/34411533/
8 217. Bell’s palsy after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33611630/
9 218. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-
10 associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1
11 nCoV-19 vaccine (AZD1222): https://pubmed.ncbi.nlm.nih.gov/33981305/
12 219. Bell’s palsy after 24 hours of mRNA-1273 SARS-CoV-2 mRNA-1273
14 220. Sequential contralateral facial nerve palsy after first and second doses of COVID-19
15 vaccine: https://pubmed.ncbi.nlm.nih.gov/34281950/.
16 221. Transverse myelitis induced by SARS-CoV-2
18 222. Peripheral facial nerve palsy after vaccination with BNT162b2 (COVID-
19 19): https://pubmed.ncbi.nlm.nih.gov/33734623/
20 223. Acute abducens nerve palsy after COVID-19
21 vaccination: https://pubmed.ncbi.nlm.nih.gov/34044114/.
22 224. Facial nerve palsy after administration of COVID-19 mRNA vaccines: analysis of
23 self-report database: https://pubmed.ncbi.nlm.nih.gov/34492394/
24 225. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine
25 for SARS-CoV-2 diplopia after COVID-19
27 226. Bell’s palsy after Ad26.COV2.S COVID-19
29 227. Bell’s palsy after COVID-19 vaccination: case
31 228. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy
32 following ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34272622/
33 229. Guillian Barré syndrome after vaccination with mRNA-1273 against COVID-
35 230. Acute facial paralysis as a possible complication of SARS-CoV-2
37 231. Bell’s palsy after COVID-19 vaccination with high antibody response in
38 CSF: https://pubmed.ncbi.nlm.nih.gov/34322761/.
39 232. Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2
40 vaccination. Comment on: “Neuralgic amyotrophy and COVID-19 infection: 2 cases of
41 accessory spinal nerve palsy” by Coll et al. Articular Spine 2021; 88:
42 10519: https://pubmed.ncbi.nlm.nih.gov/34139321/.
43 233. Bell’s palsy after a single dose of vaccine mRNA. SARS-CoV-2: case
44 report: https://pubmed.ncbi.nlm.nih.gov/34032902/.
45 234. Autoimmune hepatitis developing after coronavirus disease vaccine 2019 (COVID-
46 19): causality or victim?: https://pubmed.ncbi.nlm.nih.gov/33862041/

Page 33
1 235. Autoimmune hepatitis triggered by vaccination against SARS-CoV-

3 236. Acute autoimmune-like hepatitis with atypical antimitochondrial antibody after
4 vaccination with COVID-19 mRNA: a new clinical
5 entity: https://pubmed.ncbi.nlm.nih.gov/34293683/.
6 237. Autoimmune hepatitis after COVID
8 238. A novel case of bifacial diplegia variant of Guillain-Barré syndrome after vaccination
9 with Janssen COVID-19: https://pubmed.ncbi.nlm.nih.gov/34449715/
10 239. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and
11 Ad26.COV.2.S vaccines: https://pubmed.ncbi.nlm.nih.gov/34139631/.
12 240. Bilateral superior ophthalmic vein thrombosis, ischemic stroke and immune
13 thrombocytopenia after vaccination with ChAdOx1 nCoV-
15 241. Diagnosis and treatment of cerebral venous sinus thrombosis with vaccine-induced
16 immune-immune thrombotic
18 242. Venous sinus thrombosis after vaccination with ChAdOx1 nCov-
20 243. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an
21 analysis of cases reported to the European Medicines
22 Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
23 244. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and
24 positive SARS-CoV-2 tests: self-controlled case series
26 245. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an
27 analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/
28 246. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after
29 vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway:
30 population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
32 thromboembolic and hemorrhagic events in
33 Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
34 248. Cerebral venous thrombosis associated with COVID-19 vaccine in
35 Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/
36 249. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a
37 catastrophic variant of vaccine-induced immune-mediated thrombotic
39 250. celiac artery and splenic artery thrombosis complicated by splenic infarction 7 days
40 after the first dose of Oxford vaccine, causal relationship or
41 coincidence: https://pubmed.ncbi.nlm.nih.gov/34261633/.
42 251. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-
43 19 (VITT) vaccine-induced immune thrombotic
45 252. Thrombocytopenia after COVID-19

Page 34
1 253. Cerebral venous sinus thrombosis associated with thrombocytopenia after COVID-
2 19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33845870/.
3 254. Thrombosis with thrombocytopenia syndrome after COVID-19
4 immunization: https://pubmed.ncbi.nlm.nih.gov/34236343/
5 255. Acute myocardial infarction within 24 hours after COVID-19
7 256. Bilateral acute macular neuroretinopathy after SARS-CoV-2
9 257. central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19
10 mRNA vaccination: are these reports merely
11 coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
12 258. Intracerebral hemorrhage due to thrombosis with thrombocytopenia syndrome after
13 COVID-19 vaccination: the first fatal case in
14 Korea: https://pubmed.ncbi.nlm.nih.gov/34402235/
17 elderly Indian male treated with conventional heparin-warfarin-based
18 anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
19 260. Cerebral venous sinus thrombosis 2 weeks after first dose of SARS-CoV-2 mRNA
21 261. A case of multiple thrombocytopenia and thrombosis following vaccination with
22 ChAdOx1 nCoV-19 against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34137813/
23 262. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis
24 and adenovirus-based SARS-CoV-2
26 263. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by
27 ChAdOx1 nCov-19 vaccine: impact on recanalization
28 strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
29 264. New-onset refractory status epilepticus after ChAdOx1 nCoV-19
31 265. Thrombosis with thrombocytopenia syndrome associated with COVID-19 viral vector
33 266. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after
34 Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
35 267. Thromboaspiration infusion and fibrinolysis for portomesenteric thrombosis after
36 administration of the AstraZeneca COVID-19
38 268. Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-
39 induced immune thrombotic
41 269. Deep venous thrombosis (DVT) occurring shortly after second dose of SARS-CoV-2
42 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/33687691/
43 270. Procoagulant antibody-mediated procoagulant platelets in immune thrombotic
44 thrombocytopenia associated with SARS-CoV-2

Page 35
1 271. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of

2 cerebral venous thrombosis with high mortality rate: a case
3 series: https://pubmed.ncbi.nlm.nih.gov/34393988/.
4 272. Procoagulant microparticles: a possible link between vaccine-induced immune
5 thrombocytopenia (VITT) and cerebral sinus venous
6 thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/.
7 273. Atypical thrombosis associated with the vaccine VaxZevria® (AstraZeneca): data
8 from the French network of regional pharmacovigilance
9 centers: https://pubmed.ncbi.nlm.nih.gov/34083026/.
10 274. Acute cerebral venous thrombosis and pulmonary artery embolism associated with
11 the COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34247246/.
12 275. Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal
13 haemorrhage: https://pubmed.ncbi.nlm.nih.gov/34235757/.
14 276. Palmar digital vein thrombosis after Oxford-AstraZeneca COVID-19
16 277. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-
17 AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
18 278. Cerebral venous thrombosis following COVID-19
20 279. Lipschütz ulcers after AstraZeneca COVID-19
22 280. Amyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-
24 281. Thrombosis with thrombocytopenia after Messenger vaccine RNA-
26 282. Intracerebral hemorrhage twelve days after vaccination with ChAdOx1 nCoV-
28 283. Thrombotic thrombocytopenia after vaccination with COVID-19: in search of the
29 underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34071883/
30 284. Coronavirus (COVID-19) Vaccine-induced immune thrombotic thrombocytopenia
32 285. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe
33 using the EudraVigilance database: Thrombosis in unusual
34 sites: https://pubmed.ncbi.nlm.nih.gov/34375510/
35 286. Immunoglobulin adjuvant for vaccine-induced immune thrombotic
37 287. Severe vaccine-induced thrombotic thrombocytopenia following vaccination with
38 COVID-19: an autopsy case report and review of the
39 literature: https://pubmed.ncbi.nlm.nih.gov/34355379/.
40 288. A case of acute pulmonary embolism after immunization with SARS-CoV-2
42 289. Neurosurgical considerations regarding decompressive craniectomy for intracerebral
43 hemorrhage after SARS-CoV-2 vaccination in vaccine-induced thrombotic
44 thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
45 290. Thrombosis and SARS-CoV-2 vaccines: vaccine-induced immune thrombotic
46 thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34237213/.

Page 36
1 291. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease

2 associated with the BNT162b2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34105247/.
3 292. Immune complexes, innate immunity and NETosis in ChAdOx1 vaccine-induced
5 293. Sensory Guillain-Barré syndrome following ChAdOx1 nCov-19 vaccine: report of two
6 cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34416410/.
7 294. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19
8 (AZD1222) vaccination: https://pubmed.ncbi.nlm.nih.gov/34462013/.
9 295. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years,
10 after anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/.
11 296. Post-vaccinal encephalitis after ChAdOx1 nCov-
13 297. Neurological symptoms and neuroimaging alterations related to COVID-19 vaccine:
14 cause or coincidence?: https://pubmed.ncbi.nlm.nih.gov/34507266/
15 298. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient
16 with multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34459725/
17 299. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-
19 300. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination
20 ASIA syndrome: https://pubmed.ncbi.nlm.nih.gov/34043800/.
21 301. Facial diplegia: a rare and atypical variant of Guillain-Barré syndrome and the
22 Ad26.COV2.S vaccine: https://pubmed.ncbi.nlm.nih.gov/34447646/
23 302. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large
24 population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
25 303. fulminant myocarditis and systemic hyperinflammation temporally associated with
26 BNT162b2 COVID-19 mRNA vaccination in two
27 patients: https://pubmed.ncbi.nlm.nih.gov/34416319/.
28 304. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital,
29 centered on cerebral venous sinus thrombosis
30 (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
31 305. Induction and exacerbation of subacute cutaneous lupus erythematosus
32 erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2
34 306. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA
35 (mRNA)-based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34513435/
36 307. Hepatitis C virus reactivation after COVID-19 vaccination: a case
38 308. Bilateral immune-mediated keratolysis after immunization with SARS-CoV-2
39 recombinant viral vector vaccine: https://pubmed.ncbi.nlm.nih.gov/34483273/.
40 309. Immune-mediated thrombocytopenic purpura after Pfizer-BioNTech COVID-19
41 vaccine in an elderly woman: https://pubmed.ncbi.nlm.nih.gov/34513446/
42 310. Platelet activation and modulation in thrombosis with thrombocytopenia syndrome
43 associated with the ChAdO × 1 nCov-19
45 311. Reactive arthritis after COVID-19

Page 37
1 312. Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune /

2 inflammatory syndrome induced by
3 adjuvants: https://pubmed.ncbi.nlm.nih.gov/33858208/
4 313. Acute relapse and impaired immunization after COVID-19 vaccination in a patient
5 with multiple sclerosis treated with
6 rituximab: https://pubmed.ncbi.nlm.nih.gov/34015240/
7 314. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-
9 315. COVID-19 mRNA vaccine causing CNS inflammation: a case
10 series: https://pubmed.ncbi.nlm.nih.gov/34480607/
11 316. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-
13 317. Acute disseminated encephalomyelitis following vaccination against SARS-CoV-
15 318. Tolosa-Hunt syndrome occurring after COVID-19
17 319. Systemic capillary extravasation syndrome following vaccination with ChAdOx1
18 nCOV-19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
19 320. Immune-mediated thrombocytopenia associated with Ad26.COV2.S vaccine
20 (Janssen; Johnson & Johnson): https://pubmed.ncbi.nlm.nih.gov/34469919/.
21 321. Transient thrombocytopenia with glycoprotein-specific platelet autoantibodies after
22 vaccination with Ad26.COV2.S: case
24 322. Acute hyperactive encephalopathy following COVID-19 vaccination with dramatic
25 response to methylprednisolone: case
27 323. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19
29 324. Autoimmune hepatitis developing after ChAdOx1 nCoV-19 vaccine (Oxford-
30 AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34171435/
31 325. Severe relapse of multiple sclerosis after COVID-19 vaccination: a case
33 326. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector
34 Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34514078/
35 327. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-
37 328. IgA vasculitis in adult patient after vaccination with ChadOx1 nCoV-
39 329. A case of leukocytoclastic vasculitis after vaccination with a SARS-CoV2 vaccine:
40 case report: https://pubmed.ncbi.nlm.nih.gov/34196469/.
41 330. Onset / outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-
42 AstraZeneca / Covishield): report of two
43 cases: https://pubmed.ncbi.nlm.nih.gov/34350668/
44 331. Hailey-Hailey disease exacerbation after SARS-CoV-2
46 332. Supraclavicular lymphadenopathy after COVID-19 vaccination in Korea: serial
47 follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/.
Page 38
1 333. COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity:

2 concern in cases with underlying hepatic
3 problems: https://pubmed.ncbi.nlm.nih.gov/34509271/.
4 334. Report of the International Cerebral Venous Thrombosis Consortium on cerebral
5 venous thrombosis after SARS-CoV-2
7 335. Immune thrombocytopenia after vaccination during the COVID-19
8 pandemic: https://pubmed.ncbi.nlm.nih.gov/34435486/
9 336. COVID-19: lessons from the Norwegian tragedy should be taken into account in
10 planning for vaccine launch in less developed/developing
11 countries: https://pubmed.ncbi.nlm.nih.gov/34435142/
12 337. Rituximab-induced acute lympholysis and pancytopenia following vaccination with
13 COVID-19: https://pubmed.ncbi.nlm.nih.gov/34429981/
14 338. Exacerbation of plaque psoriasis after COVID-19 inactivated mRNA and BNT162b2
15 vaccines: report of two cases: https://pubmed.ncbi.nlm.nih.gov/34427024/
16 339. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19
18 340. Vesiculobullous cutaneous reactions induced by COVID-19 mRNA vaccine: report of
19 four cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34236711/
20 341. Vaccine-induced thrombocytopenia with severe
21 headache: https://pubmed.ncbi.nlm.nih.gov/34525282/
22 342. Acute perimyocarditis after the first dose of COVID-19 mRNA
24 343. Rhabdomyolysis and fasciitis induced by COVID-19 mRNA
26 344. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of
27 the literature: https://pubmed.ncbi.nlm.nih.gov/34363637/
28 345. Immune thrombocytopenia associated with the Pfizer-BioNTech COVID-19 mRNA
29 vaccine
30 BNT162b2: https://www.sciencedirect.com/science/article/pii/S2214250921002018
31 346. Secondary immune thrombocytopenia putatively attributable to COVID-19
32 vaccination: https://casereports.bmj.com/content/14/5/e242220.abstract.
33 347. Immune thrombocytopenia following Pfizer-BioNTech BNT162b2 mRNA COVID-19
35 348. Newly diagnosed idiopathic thrombocytopenia after COVID-19 vaccine
36 administration: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176657/.
37 349. Idiopathic thrombocytopenic purpura and the Modern Covid-19
38 vaccine: https://www.annemergmed.com/article/S0196-0644(21)00122-0/fulltext.
39 350. Thrombocytopenia after Pfizer and Moderna SARS vaccination – CoV -
40 2: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014568/.
41 351. Immune thrombocytopenic purpura and acute liver injury after COVID-19
42 vaccination: https://casereports.bmj.com/content/14/7/e242678.
43 352. Collection of complement-mediated and autoimmune-mediated hematologic
44 conditions after SARS-CoV-2
45 vaccination: https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoi
46 mmune-and-complement-mediated-hematologic

Page 39
1 353. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side
2 effects before phase 3
3 results: https://ejhp.bmj.com/content/early/2021/05/23/ejhpharm-2021-002794
4 354. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal
5 hemoglobinuria: https://ashpublications.org/blood/article/137/26/3670/475905/COVID-
6 19-vaccines-induce-severe-hemolysis-in
7 355. Cerebral venous thrombosis associated with COVID-19 vaccine in
8 Germany: https://pubmed.ncbi.nlm.nih.gov/34288044/.
9 356. Cerebral venous sinus thrombosis after COVID-19 vaccination : Neurological and
10 radiological management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
11 357. Cerebral venous thrombosis and thrombocytopenia after COVID-19
13 358. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19
14 vaccination: report of two cases in the United
15 Kingdom: https://pubmed.ncbi.nlm.nih.gov/33857630/.
16 359. Cerebral venous thrombosis induced by SARS-CoV-2
18 360. Carotid artery immune thrombosis induced by adenovirus-vectored COVID-19
19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34312301/.
20 361. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic
22 362. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced
23 immune-immune thrombotic
25 363. Cerebral venous thrombosis after the BNT162b2 mRNA SARS-CoV-2
27 364. Cerebral venous thrombosis after COVID-19
29 365. Lethal cerebral venous sinus thrombosis after COVID-19
31 366. Cerebral venous sinus thrombosis in the U.S. population, After SARS-CoV-2
32 vaccination with adenovirus and after COVID-
34 367. Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis
35 increased by intravascular administration of the
37 368. Central venous sinus thrombosis with subarachnoid hemorrhage after COVID-19
38 mRNA vaccination: are these reports merely
39 coincidental: https://pubmed.ncbi.nlm.nih.gov/34478433/
40 369. Cerebral venous sinus thrombosis after ChAdOx1 nCov-19 vaccination with a
41 misleading first brain MRI: https://pubmed.ncbi.nlm.nih.gov/34244448/
42 370. Early results of bivalirudin treatment for thrombotic thrombocytopenia and cerebral
43 venous sinus thrombosis after vaccination with
45 371. Cerebral venous sinus thrombosis associated with post-vaccination
46 thrombocytopenia by COVID-19: https://pubmed.ncbi.nlm.nih.gov/33845870/.

Page 40
1 372. Cerebral venous sinus thrombosis 2 weeks after the first dose of SARS-CoV-2
2 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34101024/.
3 373. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of
4 cerebral venous thrombosis with a high mortality rate: a case
6 374. Adenovirus interactions with platelets and coagulation and vaccine-associated
7 autoimmune thrombocytopenia thrombosis
8 syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/.
9 375. Headache attributed to COVID-19 (SARS-CoV-2 coronavirus) vaccination with the
10 ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort
12 376. Adverse effects reported after COVID-19 vaccination in a tertiary care hospital, focus
13 on cerebral venous sinus thrombosis
14 (CVST): https://pubmed.ncbi.nlm.nih.gov/34092166/
15 377. Cerebral venous sinus thrombosis following vaccination against SARS-CoV-2: an
16 analysis of cases reported to the European Medicines
17 Agency: https://pubmed.ncbi.nlm.nih.gov/34293217/
18 378. A rare case of a middle-age Asian male with cerebral venous thrombosis after
19 COVID-19 AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34274191/
22 elderly Indian male treated with conventional heparin-warfarin-based
23 anticoagulation: https://pubmed.ncbi.nlm.nih.gov/34186376/
24 380. Arterial events, venous thromboembolism, thrombocytopenia and bleeding after
25 vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway:
26 population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/
27 381. Procoagulant microparticles: a possible link between vaccine-induced immune
28 thrombocytopenia (VITT) and cerebral sinus venous
29 thrombosis: https://pubmed.ncbi.nlm.nih.gov/34129181/
30 382. S. case reports of cerebral venous sinus thrombosis with thrombocytopenia after
31 vaccination with Ad26.COV2.S, March 2-April 21,
33 383. Malignant cerebral infarction after vaccination with ChAdOx1 nCov-19: a
34 catastrophic variant of vaccine-induced immune-mediated thrombotic
36 384. Acute ischemic stroke revealing immune thrombotic thrombocytopenia induced by
37 ChAdOx1 nCov-19 vaccine: impact on recanalization
38 strategy: https://pubmed.ncbi.nlm.nih.gov/34175640/
39 385. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): a new
40 clinicopathologic entity with heterogeneous clinical
41 presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/.
42 386. Imaging and hematologic findings in thrombosis and thrombocytopenia after
43 vaccination with ChAdOx1 nCoV-19
44 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
45 387. Autoimmunity roots of thrombotic events after vaccination with COVID-

Page 41
1 388. Cerebral venous sinus thrombosis after vaccination: the UK

3 389. Massive cerebral venous thrombosis and venous basin infarction as late
4 complications of COVID-19: a case report: https://pubmed.ncbi.nlm.nih.gov/34373991/
5 390. Australian and New Zealand approach to the diagnosis and treatment of vaccine-
6 induced immune thrombosis and immune
8 391. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 /
9 polyanion antibodies in Norwegian health care workers after COVID-19
11 392. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-
12 associated ATM and 3 serious adverse events of post-vaccination ATM with ChAdOx1
13 nCoV-19 (AZD1222) vaccine: https://pubmed.ncbi.nlm.nih.gov/33981305/.
14 393. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after
15 ChAdOx1 nCoV-19 vaccine:. https://pubmed.ncbi.nlm.nih.gov/34272622/
16 394. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently
17 vaccinated with an adenoviral vector-based COVID-19
18 vaccine:. https://pubmed.ncbi.nlm.nih.gov/33877737/
19 395. Predicted and observed incidence of thromboembolic events among Koreans
20 vaccinated with the ChAdOx1 nCoV-19
23 thromboembolic, and hemorrhagic events in
24 Scotland: https://pubmed.ncbi.nlm.nih.gov/34108714/
25 397. ChAdOx1 nCoV-19 vaccine-associated thrombocytopenia: three cases of immune
26 thrombocytopenia after 107,720 doses of ChAdOx1 vaccination in
27 Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/.
28 398. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after
29 Johnson & Johnson COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261635/
30 399. Neurosurgical considerations with respect to decompressive craniectomy for
31 intracerebral hemorrhage after SARS-CoV-2 vaccination in vaccine-induced
32 thrombotic thrombocytopenia-VITT: https://pubmed.ncbi.nlm.nih.gov/34202817/
33 400. Large hemorrhagic stroke after vaccination against ChAdOx1 nCoV-19: a case
35 401. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-
37 402. A rare case of thrombosis and thrombocytopenia of the superior ophthalmic vein
38 after ChAdOx1 nCoV-19 vaccination against SARS-CoV-
40 403. Thrombosis and severe acute respiratory syndrome Coronavirus 2 vaccines:
41 vaccine-induced immune thrombotic
43 404. Renal vein thrombosis and pulmonary embolism secondary to vaccine-induced
44 thrombotic immune thrombocytopenia
45 (VITT): https://pubmed.ncbi.nlm.nih.gov/34268278/.

Page 42
1 405. Limb ischemia and pulmonary artery thrombosis after ChAdOx1 nCoV-19 vaccine
2 (Oxford-AstraZeneca): a case of vaccine-induced immune thrombotic
4 406. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large
5 population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/.
6 407. Secondary thrombocytopenia after SARS-CoV-2 vaccination: case report of
7 haemorrhage and hematoma after minor oral
8 surgery: https://pubmed.ncbi.nlm.nih.gov/34314875/.
9 408. Venous thromboembolism and mild thrombocytopenia after vaccination with
10 ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34384129/
11 409. Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia
12 syndrome after successful initial therapy with intravenous immunoglobulins: a
13 rationale for monitoring immunoglobulin G
14 levels: https://pubmed.ncbi.nlm.nih.gov/34382387/
15 410. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-
16 CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/.
17 411. Intracerebral hemorrhage associated with vaccine-induced thrombotic
18 thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant
19 woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
20 412. Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic
22 413. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-
24 414. A case of vaccine-induced immune-immune thrombotic thrombocytopenia with
25 massive arteriovenous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34059191/
26 415. Cutaneous thrombosis associated with cutaneous necrosis following Oxford-
27 AstraZeneca COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34189756/
28 416. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19
30 417. Vaccine-induced thrombocytopenia with severe
31 headache: https://pubmed.ncbi.nlm.nih.gov/34525282/
32 418. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to
33 17 years: stratified analysis of a national
34 database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1
35 419. COVID-19 mRNA vaccination and development of CMR-confirmed
36 myopericarditis: https://www.medrxiv.org/content/10.1101/2021.09.13.21262182v1.full
37 ?s=09.
38 420. Severe autoimmune hemolytic anemia after receipt of SARS-CoV-2 mRNA
39 vaccine: https://onlinelibrary.wiley.com/doi/10.1111/trf.16672
40 421. Intravenous injection of coronavirus disease 2019 (COVID-19) mRNA vaccine can
41 induce acute myopericarditis in a mouse model: https://t.co/j0IEM8cMXI
42 422. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting
43 System. (VAERS) in association with COVID-19 injectable
44 biologics: https://pubmed.ncbi.nlm.nih.gov/34601006/
45 423. This study concludes that: “The vaccine was associated with an excess risk of
46 myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious

Page 43
1 adverse event and of many other serious adverse events increased substantially after
2 SARS-CoV-2 infection”: https://www.nejm.org/doi/full/10.1056/NEJMoa2110475
3 424. Bilateral uveitis after inoculation with COVID-19 vaccine: a case
5 425. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to
6 17 years: stratified analysis of a national
7 database: https://www.medrxiv.org/content/10.1101/2021.08.30.21262866v1.
8 426. Immune-mediated hepatitis with the Moderna vaccine is no longer a coincidence but
9 confirmed: https://www.sciencedirect.com/science/article/pii/S0168827821020936
10 427. Extensive investigations revealed consistent pathophysiologic alterations after
11 vaccination with COVID-19 vaccines: https://www.nature.com/articles/s41421-021-
12 00329-3
13 428. Lobar hemorrhage with ventricular rupture shortly after the first dose of an mRNA-
14 based SARS-CoV-2
15 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8553377/
16 429. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and
17 risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a
18 caution: https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712
19 430. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with
20 thrombocytopenia syndrome:https://www.science.org/doi/10.1126/sciadv.abl8213
21 431. Lethal vaccine-induced immune thrombotic immune thrombocytopenia (VITT)
22 following announcement 26.COV2.S: first documented case outside the
23 U.S.: https://pubmed.ncbi.nlm.nih.gov/34626338/
24 432. A prothrombotic thrombocytopenic disorder resembling heparin-induced
25 thrombocytopenia after coronavirus-19
26 vaccination: https://europepmc.org/article/PPR/PPR304469 435.
27 433. VITT (vaccine-induced immune thrombotic thrombocytopenia) after vaccination with
28 ChAdOx1 nCoV-19: https://pubmed.ncbi.nlm.nih.gov/34731555/
29 434. Vaccine-induced immune thrombotic thrombocytopenia (VITT): a new
30 clinicopathologic entity with heterogeneous clinical
31 presentations: https://pubmed.ncbi.nlm.nih.gov/34159588/
32 435. Treatment of acute ischemic stroke associated with ChAdOx1 nCoV-19 vaccine-
33 induced immune thrombotic
35 436. Spectrum of neurological complications after COVID-19
37 437. Cerebral venous sinus thrombosis after vaccination: the UK
39 438. Cerebral venous vein/venous sinus thrombosis with thrombocytopenia syndrome
40 after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34373413/
41 439. Portal vein thrombosis due to vaccine-induced immune thrombotic immune
42 thrombocytopenia (VITT) after Covid vaccination with ChAdOx1 nCoV-
44 440. Hematuria, a generalized petechial rash and headaches after Oxford AstraZeneca
45 ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/
46 441. Myocardial infarction and azygos vein thrombosis after vaccination with ChAdOx1
47 nCoV-19 in a hemodialysis patient: https://pubmed.ncbi.nlm.nih.gov/34650896/
Page 44
1 442. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-

3 443. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and
4 BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with
5 teriflunomide: https://pubmed.ncbi.nlm.nih.gov/34696248/
6 444. Guillain-Barré syndrome after ChAdOx1 nCoV-19 COVID-19 vaccination: a case
8 445. Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) treated
9 with delayed therapeutic plasma exchange
10 (TPE): https://pubmed.ncbi.nlm.nih.gov/34672380/.
11 446. Rare case of COVID-19 vaccine-associated intracranial hemorrhage with venous
12 sinus thrombosis: https://pubmed.ncbi.nlm.nih.gov/34556531/.
13 447. Delayed headache after COVID-19 vaccination: a warning sign for vaccine-induced
14 cerebral venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34535076/.
15 448. Clinical features of vaccine-induced thrombocytopenia and immune
17 449. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19
18 vaccination: the FAPIC score: https://pubmed.ncbi.nlm.nih.gov/34545400/
19 450. Ischemic stroke as a presenting feature of immune thrombotic thrombocytopenia
20 induced by ChAdOx1-nCoV-19
22 451. In-hospital observational study of neurological disorders in patients recently
23 vaccinated with COVID-19 mRNA
25 452. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and
26 thrombocytopenia after vaccination with ChAdOx1 nCoV-19: report of three
28 453. Cardiovascular, neurological, and pulmonary events after vaccination with
29 BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of European
30 data: https://pubmed.ncbi.nlm.nih.gov/34710832/
31 454. Cerebral venous thrombosis developing after vaccination. COVID-19: VITT, VATT,
32 TTS and more: https://pubmed.ncbi.nlm.nih.gov/34695859/
33 455. Cerebral venous thrombosis and myeloproliferative neoplasms: a three-center study
34 of 74 consecutive cases: https://pubmed.ncbi.nlm.nih.gov/34453762/.
35 456. Possible triggers of thrombocytopenia and/or hemorrhage by BNT162b2 vaccine,
36 Pfizer-BioNTech: https://pubmed.ncbi.nlm.nih.gov/34660652/.
37 457. Multiple sites of arterial thrombosis in a 35-year-old patient after vaccination with
38 ChAdOx1 (AstraZeneca), which required emergency femoral and carotid surgical
39 thrombectomy: https://pubmed.ncbi.nlm.nih.gov/34644642/
40 458. Case series of vaccine-induced thrombotic thrombocytopenia in a London teaching
41 hospital: https://pubmed.ncbi.nlm.nih.gov/34694650/
42 459. Neuro-ophthalmic complications with thrombocytopenia and thrombosis induced by
43 ChAdOx1 nCoV-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34726934/
44 460. Thrombotic events after COVID-19 vaccination in over 50 years of age: results of a
45 population-based study in Italy: https://pubmed.ncbi.nlm.nih.gov/34835237/

Page 45
1 461. Intracerebral hemorrhage associated with vaccine-induced thrombotic

2 thrombocytopenia after ChAdOx1 nCOVID-19 vaccination in a pregnant
3 woman: https://pubmed.ncbi.nlm.nih.gov/34261297/
4 462. Age- and sex-specific incidence of cerebral venous sinus thrombosis associated with
5 Ad26.COV2.S COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34724036/.
6 463. Genital necrosis with cutaneous thrombosis following vaccination with COVID-19
8 464. Cerebral venous sinus thrombosis after mRNA-based COVID-19
10 465. COVID-19 vaccine-induced immune thrombosis with thrombocytopenia thrombosis
11 (VITT) and shades of gray in thrombus
12 formation: https://pubmed.ncbi.nlm.nih.gov/34624910/
13 466. Inflammatory myositis after vaccination with
14 ChAdOx1: https://pubmed.ncbi.nlm.nih.gov/34585145/
15 467. Acute ST-segment elevation myocardial infarction secondary to vaccine-induced
16 immune thrombosis with thrombocytopenia
17 (VITT): https://pubmed.ncbi.nlm.nih.gov/34580132/.
18 468. A rare case of COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT)
19 affecting the venosplanchnic and pulmonary arterial circulation from a UK district
20 general hospital: https://pubmed.ncbi.nlm.nih.gov/34535492/
21 469. COVID-19 vaccine-induced thrombotic thrombocytopenia: a case
23 470. Thrombosis with thrombocytopenia syndrome (TTS) after vaccination with
24 AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: a risk-benefit analysis for
25 persons <60% risk-benefit analysis for people <60 years in
26 Australia: https://pubmed.ncbi.nlm.nih.gov/34272095/
27 471. Immune thrombocytopenia after immunization with Vaxzevria ChadOx1-S vaccine
28 (AstraZeneca), Victoria, Australia: https://pubmed.ncbi.nlm.nih.gov/34756770/
29 472. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in
30 thrombotic immune thrombocytopenia induced by SARS-CoV-2
31 vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2784622
32 473. Case study of thrombosis and thrombocytopenia syndrome after administration of
33 the AstraZeneca COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34781321/
34 474. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19
35 Vaccines: https://pubmed.ncbi.nlm.nih.gov/34062319/
36 475. Cerebral venous sinus thrombosis following vaccination with ChAdOx1: the first case
37 of definite thrombosis with thrombocytopenia syndrome in
38 India: https://pubmed.ncbi.nlm.nih.gov/34706921/
39 476. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS):
40 systematic review and post hoc analysis: https://pubmed.ncbi.nlm.nih.gov/34698582/.
41 477. Case report of immune thrombocytopenia after vaccination with ChAdOx1 nCoV-
43 478. Acute transverse myelitis after COVID-19
45 479. Concerns for adverse effects of thrombocytopenia and thrombosis after adenovirus-
46 vectored COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34541935/

Page 46
1 480. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case

3 481. Cerebral venous sinus thrombosis after COVID-19 vaccination: neurologic and
4 radiologic management: https://pubmed.ncbi.nlm.nih.gov/34327553/.
5 482. Thrombocytopenia with acute ischemic stroke and hemorrhage in a patient recently
6 vaccinated with an adenoviral vector-based COVID-19
8 483. Intracerebral hemorrhage and thrombocytopenia after AstraZeneca COVID-19
9 vaccine: clinical and diagnostic challenges of vaccine-induced thrombotic
11 484. Minimal change disease with severe acute kidney injury after Oxford-AstraZeneca
12 COVID-19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34242687/.
13 485. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-
14 CoV-2 vaccine: https://pubmed.ncbi.nlm.nih.gov/34609603/
15 486. Case report: Pityriasis rosea-like rash after vaccination with COVID-
17 487. Extensive longitudinal transverse myelitis after ChAdOx1 nCOV-19 vaccine: case
19 488. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine
20 AZD1222: https://pubmed.ncbi.nlm.nih.gov/34812326/.
21 489. Thrombocytopenia, including immune thrombocytopenia after receiving COVID-19
22 mRNA vaccines reported to the Vaccine Adverse Event Reporting System
23 (VAERS): https://pubmed.ncbi.nlm.nih.gov/34006408/
24 490. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-
25 CoV-2 vaccination: victim or causality?: https://pubmed.ncbi.nlm.nih.gov/34416184/
26 491. Vaccine-induced immune thrombosis and thrombocytopenia syndrome after
27 adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: a
28 new hypothesis on mechanisms and implications for future vaccine
29 development: https://pubmed.ncbi.nlm.nih.gov/34664303/.
30 492. Thrombosis in peripheral artery disease and thrombotic thrombocytopenia following
31 adenoviral COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34649281/.
32 493. Newly diagnosed immune thrombocytopenia in a pregnant patient after coronavirus
33 disease 2019 vaccination: https://pubmed.ncbi.nlm.nih.gov/34420249/
34 494. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-
35 19 vaccines: systematic review and meta-
36 analysis: https://pubmed.ncbi.nlm.nih.gov/34610990/.
37 495. Sweet’s syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an
38 elderly woman: https://pubmed.ncbi.nlm.nih.gov/34590397/
39 496. Sudden sensorineural hearing loss after COVID-19
41 497. Prevalence of serious adverse events among health care professionals after
42 receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in
43 Togo, March 2021: https://pubmed.ncbi.nlm.nih.gov/34819146/.
44 498. Acute hemichorea-hemibalismus after COVID-19 (AZD1222)
46 499. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in
47 Italy: https://pubmed.ncbi.nlm.nih.gov/34741583/
Page 47
1 500. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case
3 501. Thrombosis after COVID-19 vaccination: possible link to ACE
4 pathways: https://pubmed.ncbi.nlm.nih.gov/34479129/
5 502. Thrombocytopenia in an adolescent with sickle cell anemia after COVID-19
7 503. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 corona virus
8 vaccine nCoV-19 (recombinant): https://pubmed.ncbi.nlm.nih.gov/34546608/
9 504. Abdominal pain and bilateral adrenal hemorrhage from immune thrombotic
10 thrombocytopenia induced by COVID-19
12 505. Longitudinally extensive cervical myelitis after vaccination with inactivated virus
13 based COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34849183/
14 506. Induction of cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19
16 507. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19
17 (AZD1222): https://pubmed.ncbi.nlm.nih.gov/34751429/.
18 508. Ocular adverse events following COVID-19
20 509. Depression after ChAdOx1-S / nCoV-19
22 510. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19
24 511. Recurrent ANCA-associated vasculitis after Oxford AstraZeneca ChAdOx1-S
25 COVID-19 vaccination: a case series of two
26 patients: https://pubmed.ncbi.nlm.nih.gov/34755433/
27 512. Major artery thrombosis and vaccination against ChAdOx1 nCov-
29 513. Rare case of contralateral supraclavicular lymphadenopathy after vaccination with
30 COVID-19: computed tomography and ultrasound
31 findings: https://pubmed.ncbi.nlm.nih.gov/34667486/
32 514. Cutaneous lymphocytic vasculitis after administration of the second dose of
33 AZD1222 (Oxford-AstraZeneca) Severe acute respiratory syndrome Coronavirus 2
34 vaccine: chance or causality: https://pubmed.ncbi.nlm.nih.gov/34726187/.
35 515. Pancreas allograft rejection after ChAdOx1 nCoV-19
37 516. Understanding the risk of thrombosis with thrombocytopenia syndrome following
38 Ad26.COV2.S vaccination: https://pubmed.ncbi.nlm.nih.gov/34595694/
39 517. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and
40 AstraZeneca vaccine COVID-19: a prospective cohort study in health care
41 workers: https://pubmed.ncbi.nlm.nih.gov/34661934/
42 518. Comments on thrombosis after vaccination: spike protein leader sequence could be
43 responsible for thrombosis and antibody-mediated
44 thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34788138
45 519. Eosinophilic dermatosis after AstraZeneca COVID-19

Page 48
1 520. Severe immune thrombocytopenia following COVID-19 vaccination: report of four

2 cases and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34653943/.
3 521. Relapse of immune thrombocytopenia after COVID-19
5 522. Thrombosis in pre- and post-vaccination phase of COVID-
6 19; https://pubmed.ncbi.nlm.nih.gov/34650382/
7 523. A look at the role of postmortem immunohistochemistry in understanding the
8 inflammatory pathophysiology of COVID-19 disease and vaccine-related thrombotic
9 adverse events: a narrative review: https://pubmed.ncbi.nlm.nih.gov/34769454/
10 524. COVID-19 vaccine in patients with hypercoagulability disorders: a clinical
11 perspective: https://pubmed.ncbi.nlm.nih.gov/34786893/
12 525. Vaccine-associated thrombocytopenia and thrombosis: venous endotheliopathy
13 leading to combined venous micro-
14 macrothrombosis: https://pubmed.ncbi.nlm.nih.gov/34833382/
15 526. Thrombosis and thrombocytopenia syndrome causing isolated symptomatic carotid
16 occlusion after COVID-19 Ad26.COV2.S vaccine
17 (Janssen): https://pubmed.ncbi.nlm.nih.gov/34670287/
18 527. An unusual presentation of acute deep vein thrombosis after Modern COVID-19
19 vaccine: case report: https://pubmed.ncbi.nlm.nih.gov/34790811/
20 528. Immediate high-dose intravenous immunoglobulins followed by direct treatment with
21 thrombin inhibitors is crucial for survival in vaccine-induced immune thrombotic
22 thrombocytopenia Sars-Covid-19-vector adenoviral VITT with venous thrombosis of
23 the cerebral sinus and portal vein: https://pubmed.ncbi.nlm.nih.gov/34023956/.
24 529. Thrombosis formation after COVID-19 vaccination immunologic aspects: review
25 article: https://pubmed.ncbi.nlm.nih.gov/34629931/
26 530. Imaging and hematologic findings in thrombosis and thrombocytopenia after
27 vaccination with ChAdOx1 nCoV-19
28 (AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34402666/
29 531. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and
30 review of the literature: https://pubmed.ncbi.nlm.nih.gov/34842783/
31 532. Cerebral venous sinus thrombosis, pulmonary embolism, and thrombocytopenia
32 after COVID-19 vaccination in a Taiwanese man: a case report and review of the
33 literature: https://pubmed.ncbi.nlm.nih.gov/34630307/
34 533. Fatal cerebral venous sinus thrombosis after COVID-19
36 534. Autoimmune roots of thrombotic events after COVID-19
38 535. New portal vein thrombosis in cirrhosis: is thrombophilia exacerbated by vaccine or
39 COVID-19: https://www.jcehepatology.com/article/S0973-6883(21)00545-4/fulltext.
40 536. Images of immune thrombotic thrombocytopenia induced by Oxford / AstraZeneca®
41 COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33962903/.
42 537. Cerebral venous sinus thrombosis after vaccination with COVID-19 mRNA of
43 BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34796065/.
44 538. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19
45 vaccination in health care workers taking ACE
46 inhibitors: https://pubmed.ncbi.nlm.nih.gov/34579248/

Page 49
1 539. A case of unusual mild clinical presentation of COVID-19 vaccine-induced immune

2 thrombotic thrombocytopenia with splanchnic vein
3 thrombosis: https://pubmed.ncbi.nlm.nih.gov/34843991/
4 540. Cerebral venous sinus thrombosis following vaccination with Pfizer-BioNTech
5 COVID-19 (BNT162b2): https://pubmed.ncbi.nlm.nih.gov/34595867/
6 541. A case of idiopathic thrombocytopenic purpura after a booster dose of COVID-19
7 BNT162b2 vaccine (Pfizer-Biontech): https://pubmed.ncbi.nlm.nih.gov/34820240/
8 542. Vaccine-induced immune thrombotic immune thrombocytopenia (VITT): targeting
9 pathologic mechanisms with Bruton’s tyrosine kinase
10 inhibitors: https://pubmed.ncbi.nlm.nih.gov/33851389/
11 543. Thrombotic thrombocytopenic purpura after vaccination with Ad26.COV2-
12 S: https://pubmed.ncbi.nlm.nih.gov/33980419/
13 544. Thromboembolic events in younger females exposed to Pfizer-BioNTech or Moderna
14 COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34264151/
15 545. Potential risk of thrombotic events after COVID-19 vaccination with Oxford-
16 AstraZeneca in women receiving
17 estrogen: https://pubmed.ncbi.nlm.nih.gov/34734086/
18 546. Thrombosis after adenovirus-vectored COVID-19 vaccination: a concern for
19 underlying disease: https://pubmed.ncbi.nlm.nih.gov/34755555/
20 547. Adenovirus interactions with platelets and coagulation and vaccine-induced immune
21 thrombotic thrombocytopenia syndrome: https://pubmed.ncbi.nlm.nih.gov/34407607/
22 548. Thrombotic thrombocytopenic purpura: a new threat after COVID bnt162b2
24 549. Unusual site of deep vein thrombosis after vaccination against coronavirus mRNA-
25 2019 coronavirus disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34840204/
26 550. Neurological side effects of SARS-CoV-2
28 551. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of
29 SARS-CoV-2 spike protein and adenovirus vector-activated signaling
30 pathways: https://pubmed.ncbi.nlm.nih.gov/34639132/
31 552. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review
32 of acute pulmonary embolism complications and follow-
33 up: https://pubmed.ncbi.nlm.nih.gov/34804412/
34 553. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case
36 554. Complicated case report of long-term vaccine-induced thrombotic immune
37 thrombocytopenia A: https://pubmed.ncbi.nlm.nih.gov/34835275/.
38 555. Deep venous thrombosis after vaccination with Ad26.COV2.S in adult
39 males: https://pubmed.ncbi.nlm.nih.gov/34659839/.
40 556. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case
42 557. Severe autoimmune hemolytic autoimmune anemia after receiving SARS-CoV-2
43 mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34549821/
44 558. Occurrence of COVID-19 variants among recipients of ChAdOx1 nCoV-19 vaccine
45 (recombinant): https://pubmed.ncbi.nlm.nih.gov/34528522/

Page 50
1 559. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies, and elevated D-

2 dimer in Thais after vaccination with ChAdOx1 nCoV-
4 560. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-
5 vaccination: https://academic.oup.com/cid/advance-article-
6 abstract/doi/10.1093/cid/ciab989/644 5179.
7 561. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and
8 determination of incidence rate: https://academic.oup.com/cid/advance-
9 article/doi/10.1093/cid/ciab926/6420408
10 562. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and
11 vaccine types: https://www.mdpi.com/2075-4426/11/11/1106
15 564. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and
16 non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
17 565. Myocarditis Following mRNA COVID-19 Vaccine: https://journals.lww.com/pec-
18 online/Abstract/2021/11000/Myocarditis_Following_
19 mRNA_COVID_19_Vaccine.9.aspx.
20 566. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in
21 Israel: https://pubmed.ncbi.nlm.nih.gov/34614328/.
22 567. Myocarditis, pericarditis, and cardiomyopathy following COVID-19
23 vaccination: https://www.heartlungcirc.org/article/S1443-9506(21)01156-2/fulltext
24 568. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based
25 COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34277198/
26 569. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and
27 CMR Findings: https://pubmed.ncbi.nlm.nih.gov/34246586/
28 570. Hypersensitivity Myocarditis and COVID-19
29 Vaccines: https://pubmed.ncbi.nlm.nih.gov/34856634/.
30 571. Severe myocarditis associated with COVID-19 vaccine: zebra or
31 unicorn?: https://www.internationaljournalofcardiology.com/article/S0167-
32 5273(21)01477-7/fulltext.
33 572. Acute myocardial infarction and myocarditis after COVID-19
34 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8522388/
35 573. Myocarditis after Covid-19 vaccination in a large healthcare
36 organization: https://www.nejm.org/doi/10.1056/NEJMoa2110737
37 574. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a
38 case series of
39 children: https://jamanetwork.com/journals/jamacardiology/fullarticle/2783052
40 575. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in
41 adolescents and young
42 adults: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583?
43 url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
44 576. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA
45 vaccination:. https://pubmed.ncbi.nlm.nih.gov/34756746/

Page 51
1 577. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases
2 from a regional pharmacovigilance
3 center: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8587334/
4 578. Myocarditis after COVID-19 mRNA
5 vaccines: https://pubmed.ncbi.nlm.nih.gov/34546329/.
6 579. Patients with acute myocarditis after COVID-19 mRNA
7 vaccination:. https://jamanetwork.com/journals/jamacardiology/fullarticle/2781602.
8 580. Myocarditis after COVID-19 vaccination: a case
9 series: https://www.sciencedirect.com/science/article/pii/S0264410X21011725?via%3
10 Dihub.
11 581. Myocarditis associated with COVID-19 vaccination in
12 adolescents: https://publications.aap.org/pediatrics/article/148/5/e2021053427/181357
13 582. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with
14 COVID-19 mRNA in adolescents:. https://pubmed.ncbi.nlm.nih.gov/34704459/
15 583. Myocarditis after COVID-19 vaccination: magnetic resonance imaging
16 study: https://academic.oup.com/ehjcimaging/advance-
17 article/doi/10.1093/ehjci/jeab230/6 421640.
18 584. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19
19 vaccine: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8599115/
20 585. Myocarditis after COVID-19
22 586. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with
23 arrhythmogenic left ventricular
24 cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/.
26 19: https://www.revespcardiol.org/en-linkresolver-acute-myocarditis-after-
27 administration-bnt162b2-S188558572100133X.
28 588. Myocarditis associated with COVID-19 mRNA
29 vaccination: https://pubs.rsna.org/doi/10.1148/radiol.2021211430
30 589. Acute myocarditis after COVID-19 vaccination: a case
32 590. Acute myopericarditis after COVID-19 vaccination in
33 adolescents:. https://pubmed.ncbi.nlm.nih.gov/34589238/.
35 vaccination: https://academic.oup.com/jpids/article/10/10/962/6329543.
36 592. Acute myocarditis associated with anti-COVID-19
37 vaccination: https://ecevr.org/DOIx.php?id=10.7774/cevr.2021.10.2.196.
38 593. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT,
39 and MRI findings:. https://pubmed.ncbi.nlm.nih.gov/34428917/.
40 594. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19
41 vaccination:. https://pubmed.ncbi.nlm.nih.gov/34088762/.
42 595. Myocarditis and pericarditis in adolescents after first and second doses of COVID-19
43 mRNA vaccines:. https://academic.oup.com/ehjqcco/advance-
44 article/doi/10.1093/ehjqcco/qcab090/64 42104.
45 596. COVID 19 vaccine for adolescents. Concern for myocarditis and
46 pericarditis: https://www.mdpi.com/2036-7503/13/3/61.

Page 52
1 597. Cardiac imaging of acute myocarditis after vaccination with COVID-19

3 598. Myocarditis temporally associated with COVID-19
5 599. Acute myocardial injury after COVID-19 vaccination: a case report and review of
6 current evidence from the vaccine adverse event reporting system
7 database: https://pubmed.ncbi.nlm.nih.gov/34219532/
8 600. Acute myocarditis associated with COVID-19 vaccination: report of a
9 case: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8639400/
10 601. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case
12 602. Myocarditis in the setting of a recent COVID-19
14 603. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two
15 cases: https://www.clinicalimaging.org/article/S0899-7071(21)00265-5/fulltext.
16 604. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-
17 dimer in Thais after vaccination with ChAdOx1 nCoV-
20 vaccination: https://academic.oup.com/cid/advance-article-
21 abstract/doi/10.1093/cid/ciab989/6445179
22 606. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and
23 incidence rate determination: https://academic.oup.com/cid/advance-
24 article/doi/10.1093/cid/ciab926/6420408.
25 607. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and
26 vaccine types: https://www.mdpi.com/2075-4426/11/11/1106
30 609. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and
31 non-COVID-19 vaccine recipients: https://pubmed.ncbi.nlm.nih.gov/34696294/
32 610. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine:
33 case report: https://pubmed.ncbi.nlm.nih.gov/34615534/
34 611. Three cases of acute venous thromboembolism in women after coronavirus 2019
36 612. Clinical and biological features of cerebral venous sinus thrombosis after vaccination
37 with ChAdOx1 nCov-19; https://jnnp.bmj.com/content/early/2021/09/29/jnnp-2021-
38 327340.
39 613. COV2-S vaccination may reveal hereditary thrombophilia: massive cerebral venous
40 sinus thrombosis in a young man with normal platelet
41 count: https://pubmed.ncbi.nlm.nih.gov/34632750/
42 614. Post-mortem findings in vaccine-induced thrombotic
43 thrombocytopenia: https://haematologica.org/article/view/haematol.2021.279075
44 615. COVID-19 vaccine-induced thrombosis: https://pubmed.ncbi.nlm.nih.gov/34802488/.
45 616. Inflammation and platelet activation after COVID-19 vaccines: possible mechanisms
46 behind vaccine-induced immune thrombocytopenia and
Page 53
1 617. Anaphylactoid reaction and coronary thrombosis related to COVID-19 mRNA

3 618. Vaccine-induced cerebral venous thrombosis and thrombocytopenia. Oxford-
4 AstraZeneca COVID-19: a missed opportunity for rapid return on
5 experience: https://www.sciencedirect.com/science/article/pii/S235255682100093X
6 619. Occurrence of splenic infarction due to arterial thrombosis after vaccination with
7 COVID-19: https://pubmed.ncbi.nlm.nih.gov/34876440/
8 620. Deep venous thrombosis more than two weeks after COVID-19
10 621. Case report: Take a second look: Cerebral venous thrombosis related to Covid-19
11 vaccination and thrombotic thrombocytopenia
13 622. Information on ChAdOx1 nCoV-19 vaccine-induced immune-mediated thrombotic
15 623. Change in blood viscosity after COVID-19 vaccination: estimation for persons with
16 underlying metabolic syndrome: https://pubmed.ncbi.nlm.nih.gov/34868465/
17 624. Management of a patient with a rare congenital limb malformation syndrome after
18 SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia
20 625. Bilateral thalamic stroke: a case of COVID-19 (VITT) vaccine-induced immune
21 thrombotic thrombocytopenia or a coincidence due to underlying risk
22 factors: https://pubmed.ncbi.nlm.nih.gov/34820232/.
23 626. Thrombocytopenia and splanchnic thrombosis after vaccination with Ad26.COV2.S
24 successfully treated with transjugular intrahepatic intrahepatic portosystemic shunt
25 and thrombectomy: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26258
26 627. Incidence of acute ischemic stroke after coronavirus vaccination in Indonesia: case
28 628. Successful treatment of vaccine-induced immune immune thrombotic
29 thrombocytopenia in a 26-year-old female
30 patient: https://pubmed.ncbi.nlm.nih.gov/34614491/
31 629. Case report: vaccine-induced immune immune thrombotic thrombocytopenia in a
32 patient with pancreatic cancer after vaccination with messenger RNA-
34 630. Idiopathic idiopathic external jugular vein thrombophlebitis after coronavirus disease
35 vaccination (COVID-19): https://pubmed.ncbi.nlm.nih.gov/33624509/.
36 631. Squamous cell carcinoma of the lung with hemoptysis following vaccination with
37 tozinameran (BNT162b2, Pfizer-
38 BioNTech): https://pubmed.ncbi.nlm.nih.gov/34612003/
39 632. Vaccine-induced thrombotic thrombocytopenia after Ad26.COV2.S vaccination in a
40 man presenting as acute venous
41 thromboembolism: https://pubmed.ncbi.nlm.nih.gov/34096082/
42 633. Myocarditis associated with COVID-19 vaccination in three adolescent
43 boys: https://pubmed.ncbi.nlm.nih.gov/34851078/.
44 634. Cardiovascular magnetic resonance findings in young adult patients with acute
45 myocarditis after COVID-19 mRNA vaccination: a case

Page 54
1 635. Perimyocarditis after vaccination with COVID-

5 637. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in
6 Korea: case report focusing on histopathological
8 638. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or
9 older: https://pubmed.ncbi.nlm.nih.gov/34605853/
10 639. Recurrence of acute myocarditis temporally associated with receipt of the 2019
11 coronavirus mRNA disease vaccine (COVID-19) in an adolescent
12 male: https://pubmed.ncbi.nlm.nih.gov/34166671/
13 640. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-
14 19) mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34744118/
15 641. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old
16 male: https://pubmed.ncbi.nlm.nih.gov/34334935/.
17 642. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after
18 vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34746968/
19 643. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an
20 accidental coincidence or rather a vaccination-associated autoimmune
21 myocarditis?”: https://pubmed.ncbi.nlm.nih.gov/34333695/.
22 644. Self-limited myocarditis presenting with chest pain and ST-segment elevation in
23 adolescents after vaccination with BNT162b2 mRNA
25 645. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of
26 the U.S. Military: https://pubmed.ncbi.nlm.nih.gov/34185045/
27 646. Myocarditis after BNT162b2 vaccination in a healthy
28 male: https://pubmed.ncbi.nlm.nih.gov/34229940/
29 647. Myopericarditis in a previously healthy adolescent male after COVID-19 vaccination:
30 Case report: https://pubmed.ncbi.nlm.nih.gov/34133825/
31 648. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA
33 649. Chest pain with abnormal electrocardiogram redevelopment after injection of
34 COVID-19 vaccine manufactured by
35 Moderna: https://pubmed.ncbi.nlm.nih.gov/34866106/
36 650. Biopsy-proven lymphocytic myocarditis after first vaccination with COVID-19 mRNA
37 in a 40-year-old man: case report: https://pubmed.ncbi.nlm.nih.gov/34487236/
38 651. Multimodality imaging and histopathology in a young man presenting with fulminant
39 lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-
41 652. Report of a case of myopericarditis after vaccination with BNT162b2 COVID-19
42 mRNA in a young Korean male: https://pubmed.ncbi.nlm.nih.gov/34636504/
43 653. Acute myocarditis after Comirnaty vaccination in a healthy male with previous
44 SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34367386/
45 654. Acute myocarditis in a young adult two days after vaccination with
46 Pfizer: https://pubmed.ncbi.nlm.nih.gov/34709227/

Page 55
1 655. Case report: acute fulminant myocarditis and cardiogenic shock after messenger
2 RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary
3 resuscitation: https://pubmed.ncbi.nlm.nih.gov/34778411/
4 656. Acute myocarditis after 2019 coronavirus disease
6 657. A series of patients with myocarditis after vaccination against SARS-CoV-2 with
7 mRNA-1279 and BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34246585/
8 658. Myopericarditis after Pfizer messenger ribonucleic acid coronavirus coronavirus
9 disease vaccine in adolescents: https://pubmed.ncbi.nlm.nih.gov/34228985/
10 659. Post-vaccination multisystem inflammatory syndrome in adults without evidence of
11 prior SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34852213/
12 660. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus
13 disease: https://pubmed.ncbi.nlm.nih.gov/34866122/
14 661. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-
16 662. Myocarditis following COVID-19 vaccination: MRI
17 study: https://pubmed.ncbi.nlm.nih.gov/34739045/.
18 663. Acute myocarditis after COVID-19 vaccination: case
19 report: https://docs.google.com/document/d/1Hc4bh_qNbZ7UVm5BLxkRdMPnnI9zcC
20 sl/e
21 664. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine
22 COVID-19 in a case series of children: https://pubmed.ncbi.nlm.nih.gov/34374740/
23 665. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in
24 adolescents and young adults: https://pubmed.ncbi.nlm.nih.gov/34865500/
25 666. Myocarditis following vaccination with Covid-19 in a large healthcare
26 organization: https://pubmed.ncbi.nlm.nih.gov/34614329/
27 667. AstraZeneca COVID-19 vaccine and Guillain-Barré syndrome in Tasmania: a causal
28 link: https://pubmed.ncbi.nlm.nih.gov/34560365/
29 668. COVID-19, Guillain-Barré and vaccineA dangerous
30 mix: https://pubmed.ncbi.nlm.nih.gov/34108736/.
31 669. Guillain-Barré syndrome after the first dose of Pfizer-BioNTech COVID-19 vaccine:
32 case report and review of reported cases: https://pubmed.ncbi.nlm.nih.gov/34796417/.
33 670. Guillain-Barre syndrome after BNT162b2 COVID-19
34 vaccine: https://link.springer.com/article/10.1007%2Fs10072-021-05523-5.
35 671. COVID-19 adenovirus vaccines and Guillain-Barré syndrome with facial
36 palsy: https://onlinelibrary.wiley.com/doi/10.1002/ana.26258.
37 672. Association of receipt association of Ad26.COV2.S COVID-19 vaccine with
38 presumed Guillain-Barre syndrome, February-July
39 2021: https://jamanetwork.com/journals/jama/fullarticle/2785009
40 673. A case of Guillain-Barré syndrome after Pfizer COVID-19
42 674. Guillain-Barré syndrome associated with COVID-19
44 675. Rate of recurrent Guillain-Barré syndrome after COVID-19 BNT162b2 mRNA
45 vaccine: https://jamanetwork.com/journals/jamaneurology/fullarticle/2783708
46 676. Guillain-Barre syndrome after COVID-19 vaccination in an
47 adolescent: https://www.pedneur.com/article/S0887-8994(21)00221-6/fulltext.
Page 56
1 677. Guillain-Barre syndrome after ChAdOx1-S / nCoV-19

3 678. Guillain-Barre syndrome after COVID-19 mRNA-1273 vaccine: case
5 679. Guillain-Barre syndrome following SARS-CoV-2 vaccination in 19
6 patients: https://pubmed.ncbi.nlm.nih.gov/34644738/.
7 680. Guillain-Barre syndrome presenting with facial diplegia following vaccination with
8 COVID-19 in two patients: https://pubmed.ncbi.nlm.nih.gov/34649856/
9 681. A rare case of Guillain-Barré syndrome after COVID-19
11 682. Neurological complications of COVID-19: Guillain-Barre syndrome after Pfizer
12 COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33758714/
13 683. COVID-19 vaccine causing Guillain-Barre syndrome, an uncommon potential side
14 effect: https://pubmed.ncbi.nlm.nih.gov/34484780/
15 684. Guillain-Barre syndrome after the first dose of COVID-19 vaccination: case
16 report; https://pubmed.ncbi.nlm.nih.gov/34779385/.
17 685. Miller Fisher syndrome after Pfizer COVID-19
19 686. Miller Fisher syndrome after 2019 BNT162b2 mRNA coronavirus
21 687. Bilateral facial weakness with a variant of paresthesia of Guillain-Barre syndrome
22 after Vaxzevria COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34261746/
23 688. Guillain-Barre syndrome after the first injection of ChAdOx1 nCoV-19 vaccine: first
25 689. A case of sensory ataxic Guillain-Barre syndrome with immunoglobulin G anti-GM1
26 antibodies after first dose of COVID-19 BNT162b2 mRNA vaccine
27 (Pfizer): https://pubmed.ncbi.nlm.nih.gov/34871447/
28 690. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup
29 disproportionality analysis in VigiBase: https://pubmed.ncbi.nlm.nih.gov/34579259/
30 691. A variant of Guillain-Barré syndrome after SARS-CoV-2 vaccination:
31 AMSAN: https://pubmed.ncbi.nlm.nih.gov/34370408/.
32 692. A rare variant of Guillain-Barré syndrome after vaccination with
33 Ad26.COV2.S: https://pubmed.ncbi.nlm.nih.gov/34703690/.
34 693. Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous
35 vaccine-associated Guillain-Barré
37 694. Guillain-Barré syndrome in an Australian state using mRNA and adenovirus-vector
38 SARS-CoV-2 vaccines: https://onlinelibrary.wiley.com/doi/10.1002/ana.26218.
39 695. Acute transverse myelitis after SARS-CoV-2 vaccination: case report and review of
40 the literature: https://pubmed.ncbi.nlm.nih.gov/34482455/.
41 696. Variant Guillain-Barré syndrome occurring after SARS-CoV-2
43 697. Guillian-Barre syndrome with axonal variant temporally associated with Modern
44 SARS-CoV-2 mRNA-based vaccine: https://pubmed.ncbi.nlm.nih.gov/34722067/
45 698. Guillain-Barre syndrome after the first dose of SARS-CoV-2 vaccine: a temporary
46 occurrence, not a causal association: https://pubmed.ncbi.nlm.nih.gov/33968610/

Page 57
1 699. SARS-CoV-2 vaccines can be complicated not only by Guillain-Barré syndrome but
2 also by distal small fiber neuropathy: https://pubmed.ncbi.nlm.nih.gov/34525410/
3 700. Clinical variant of Guillain-Barré syndrome with prominent facial diplegia after
4 AstraZeneca 2019 coronavirus disease
6 701. Adverse event reporting and risk of Bell’s palsy after COVID-19
7 vaccination: https://www.thelancet.com/journals/laninf/article/PIIS1473-
8 3099(21)00646-0/fulltext.
9 702. Bilateral facial nerve palsy and COVID-19 vaccination: causality or
10 coincidence: https://pubmed.ncbi.nlm.nih.gov/34522557/
11 703. Left Bell’s palsy after the first dose of mRNA-1273 SARS-CoV-2 vaccine: case
13 704. Bell’s palsy after inactivated vaccination with COVID-19 in a patient with a history of
14 recurrent Bell’s palsy: case report: https://pubmed.ncbi.nlm.nih.gov/34621891/
15 705. Neurological complications after the first dose of COVID-19 vaccines and SARS-
16 CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34697502/
17 706. Type I interferons as a potential mechanism linking COVID-19 mRNA vaccines with
18 Bell’s palsy: https://pubmed.ncbi.nlm.nih.gov/33858693/
19 707. Acute transverse myelitis following inactivated COVID-19
21 708. Acute transverse myelitis after COVID-19
23 709. A case of longitudinally extensive transverse myelitis following Covid-19
25 710. Post COVID-19 transverse myelitis; a case report with review of the
26 literature: https://pubmed.ncbi.nlm.nih.gov/34457267/.
27 711. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated
28 virus for COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/
29 712. Neuromyelitis optica in a healthy woman after vaccination against severe acute
30 respiratory syndrome coronavirus 2 mRNA-
32 713. Acute bilateral bilateral optic neuritis/chiasm with longitudinal extensive transverse
33 myelitis in long-standing stable multiple sclerosis after vector-based vaccination
34 against SARS-CoV-2: https://pubmed.ncbi.nlm.nih.gov/34131771/
35 714. A case series of acute pericarditis after vaccination with COVID-19 in the context of
36 recent reports from Europe and the United
37 States: https://pubmed.ncbi.nlm.nih.gov/34635376/
38 715. Acute pericarditis and cardiac tamponade after vaccination with Covid-
40 716. Myocarditis and pericarditis in adolescents after the first and second doses of
41 COVID-19 mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34849667/
44 718. Acute myopericarditis after COVID-19 vaccine in
45 adolescents: https://pubmed.ncbi.nlm.nih.gov/34589238/
46 719. Pericarditis after administration of the BNT162b2 mRNA vaccine COVID-
Page 58
1 720. Case report: symptomatic pericarditis post COVID-19

3 721. An outbreak of Still’s disease after COVID-19 vaccination in a 34-year-old
4 patient: https://pubmed.ncbi.nlm.nih.gov/34797392/
5 722. Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1
6 nCoV-19): https://pubmed.ncbi.nlm.nih.gov/34862234/
7 723. Myocarditis after SARS-CoV-2 mRNA vaccination, a case
9 724. Miller-Fisher syndrome and Guillain-Barré syndrome overlap syndrome in a patient
10 after Oxford-AstraZeneca SARS-CoV-2
12 725. Immune-mediated disease outbreaks or new-onset disease in 27 subjects after
13 mRNA/DNA vaccination against SARS-CoV-
15 726. Post-mortem investigation of deaths after vaccination with COVID-19
17 727. Acute kidney injury with macroscopic hematuria and IgA nephropathy after COVID-
19 728. Relapse of immune thrombocytopenia after covid-19 vaccination in young male
20 patient: https://pubmed.ncbi.nlm.nih.gov/34804803/.
21 729. Immune thrombocytopenic purpura associated with COVID-19 mRNA vaccine
22 Pfizer-BioNTech BNT16B2b2: https://pubmed.ncbi.nlm.nih.gov/34077572/
23 730. Retinal hemorrhage after SARS-CoV-2
25 731. Case report: anti-neutrophil cytoplasmic antibody-associated vasculitis with acute
26 renal failure and pulmonary hemorrhage can occur after COVID-19
28 732. Intracerebral hemorrhage due to vasculitis following COVID-19 vaccination: case
30 733. Peduncular, symptomatic cavernous bleeding after immune thrombocytopenia-
31 induced SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34549178/.
32 734. Brain death in a vaccinated patient with COVID-19
33 infection: https://pubmed.ncbi.nlm.nih.gov/34656887/
34 735. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA
36 736. Lobar hemorrhage with ventricular rupture shortly after the first dose of a SARS-
37 CoV-2 mRNA-based SARS-CoV-2
39 737. A case of outbreak of macroscopic hematuria and IgA nephropathy after SARS-CoV-
41 738. Acral hemorrhage after administration of the second dose of SARS-CoV-2 vaccine.
42 A post-vaccination reaction: https://pubmed.ncbi.nlm.nih.gov/34092400/742.
43 739. Severe immune thrombocytopenic purpura after SARS-CoV-2
45 740. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination
46 in 2 patients with IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/33771584/

Page 59
1 741. Autoimmune encephalitis after ChAdOx1-S SARS-CoV-2

3 742. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility
4 diagnosis: https://pubmed.ncbi.nlm.nih.gov/34073536/
5 743. Bell’s palsy after vaccination with mRNA (BNT162b2) and inactivated (CoronaVac)
6 SARS-CoV-2 vaccines: a case series and a nested case-control
8 744. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario,
9 Canada: by vaccine product, schedule, and
10 interval: https://www.medrxiv.org/content/10.1101/2021.12.02.21267156v1
11 745. Anaphylaxis following Covid-19 vaccine in a patient with cholinergic
12 urticaria: https://pubmed.ncbi.nlm.nih.gov/33851711/
13 746. Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results
14 of revaccination: https://pubmed.ncbi.nlm.nih.gov/34675550/.
15 747. Anaphylaxis after Modern COVID-19
17 748. Association of self-reported history of high-risk allergy with allergy symptoms after
18 COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34698847/
19 749. Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-
21 750. Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-
22 BioNTech COVID-19 vaccine – United States, December 14 to 23,
24 751. Allergic reactions, including anaphylaxis, after receiving the first dose of Modern
25 COVID-19 vaccine – United States, December 21, 2020 to January 10,
27 752. Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report
28 and mechanism of action: https://pubmed.ncbi.nlm.nih.gov/33834172/
29 753. Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis
30 following vaccination with Pfizer
31 BNT162b2: https://pubmed.ncbi.nlm.nih.gov/34579211/
32 754. Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease
33 vaccine with positive polysorbate 80 skin test
34 result: https://pubmed.ncbi.nlm.nih.gov/34343674/
35 755. Acute myocardial infarction and myocarditis after COVID-19
37 756. Takotsubo syndrome after COVID-19
39 757. Takotsubo cardiomyopathy after coronavirus 2019 vaccination in patient on
40 maintenance hemodialysis: https://pubmed.ncbi.nlm.nih.gov/34731486/.
41 758. Premature myocardial infarction or side effect of COVID-19
43 759. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA
44 COVID-19 vaccine in persons aged 75 years or
45 older: https://pubmed.ncbi.nlm.nih.gov/34807248/
46 760. Kounis syndrome type 1 induced by inactivated SARS-COV-2
Page 60
1 761. Acute myocardial infarction within 24 hours after COVID-19 vaccination: is Kounis
2 syndrome the culprit: https://pubmed.ncbi.nlm.nih.gov/34702550/
3 762. Deaths associated with the recently launched SARS-CoV-2 vaccination
4 (Comirnaty®): https://pubmed.ncbi.nlm.nih.gov/33895650/
5 763. Deaths associated with recently launched SARS-CoV-2
7 764. A case of acute encephalopathy and non-ST-segment elevation myocardial
8 infarction after vaccination with mRNA-1273: possible adverse
9 effect: https://pubmed.ncbi.nlm.nih.gov/34703815/
10 765. COVID-19 vaccine-induced urticarial
11 vasculitis: https://pubmed.ncbi.nlm.nih.gov/34369046/.
12 766. ANCA-associated vasculitis after Pfizer-BioNTech COVID-19
14 767. New-onset leukocytoclastic vasculitis after COVID-19
16 768. Cutaneous small vessel vasculitis after COVID-19
18 769. Outbreak of leukocytoclastic vasculitis after COVID-19
20 770. Leukocytoclastic vasculitis after exposure to COVID-19
22 771. Vasculitis and bursitis in [ 18 F] FDG-PET/CT after COVID-19 mRNA vaccine: post
23 hoc ergo propter hoc?; https://pubmed.ncbi.nlm.nih.gov/34495381/.
24 772. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA
25 vaccine: https://pubmed.ncbi.nlm.nih.gov/34327795
26 773. Cutaneous leukocytoclastic vasculitis induced by Sinovac COVID-19
28 774. Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and
29 crescentic Pauci-Inmune glomerulonephritis after vaccination with Pfizer-BioNTech
30 COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34659268/
31 775. Reactivation of IgA vasculitis after vaccination with COVID-
33 776. Varicella-zoster virus-related small-vessel vasculitis after Pfizer-BioNTech COVID-19
35 777. Imaging in vascular medicine: leukocytoclastic vasculitis after COVID-19 vaccine
36 booster: https://pubmed.ncbi.nlm.nih.gov/34720009/
37 778. A rare case of Henoch-Schönlein purpura after a case report of COVID-19
39 779. Cutaneous vasculitis following COVID-19
41 780. Possible case of COVID-19 mRNA vaccine-induced small-vessel
42 vasculitis: https://pubmed.ncbi.nlm.nih.gov/34705320/.
43 781. IgA vasculitis following COVID-19 vaccination in an
44 adult: https://pubmed.ncbi.nlm.nih.gov/34779011/
45 782. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
46 following vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34451967/

Page 61
1 783. Coronavirus disease vaccine 2019 (COVID-19) in systemic lupus erythematosus and
2 neutrophil anti-cytoplasmic antibody-associated
3 vasculitis: https://pubmed.ncbi.nlm.nih.gov/33928459/
4 784. Reactivation of IgA vasculitis after COVID-19
6 785. Clinical and histopathologic spectrum of delayed adverse skin reactions after
7 COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34292611/.
8 786. First description of immune complex vasculitis after COVID-19 vaccination with
9 BNT162b2: case report: https://pubmed.ncbi.nlm.nih.gov/34530771/.
10 787. Nephrotic syndrome and vasculitis after SARS-CoV-2 vaccine: true association or
11 circumstantial: https://pubmed.ncbi.nlm.nih.gov/34245294/.
12 788. Occurrence of de novo cutaneous vasculitis after vaccination against coronavirus
13 disease (COVID-19): https://pubmed.ncbi.nlm.nih.gov/34599716/.
14 789. Asymmetric cutaneous vasculitis after COVID-19 vaccination with unusual
15 preponderance of eosinophils: https://pubmed.ncbi.nlm.nih.gov/34115904/.
16 790. Henoch-Schönlein purpura occurring after vaccination with COVID-
18 791. Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine:
19 case report: https://pubmed.ncbi.nlm.nih.gov/34696186/.
20 792. Granulomatous vasculitis after AstraZeneca anti-SARS-CoV-2
22 793. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with
23 BNT162b2 COVID-19 mRNA: https://pubmed.ncbi.nlm.nih.gov/34851795/.
24 794. A case of generalized Sweet’s syndrome with vasculitis triggered by recent
25 vaccination with COVID-19: https://pubmed.ncbi.nlm.nih.gov/34849386/
26 795. Small-vessel vasculitis following Oxford-AstraZeneca vaccination against SARS-
27 CoV-2: https://pubmed.ncbi.nlm.nih.gov/34310763/
28 796. Relapse of microscopic polyangiitis after COVID-19 vaccination: case
30 797. Cutaneous vasculitis after severe acute respiratory syndrome coronavirus 2
32 798. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria
33 on cyclosporine treatment – A report of 3
35 799. Leukocytoclastic vasculitis after coronavirus disease vaccination
36 2019: https://pubmed.ncbi.nlm.nih.gov/34713472/803
37 800. Outbreaks of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-
39 801. Cutaneous small-vessel vasculitis after vaccination with a single dose of Janssen
41 802. Case of immunoglobulin A vasculitis after vaccination against coronavirus disease
43 803. Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA
44 booster vaccination: case
45 report: https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/
46 804. COVID-19 mRNA vaccination-induced lymphadenopathy mimics lymphoma
47 progression on FDG PET / CT: https://pubmed.ncbi.nlm.nih.gov/33591026/
Page 62
1 805. Lymphadenopathy in COVID-19 vaccine recipients: diagnostic dilemma in oncology

2 patients: https://pubmed.ncbi.nlm.nih.gov/33625300/
3 806. Hypermetabolic lymphadenopathy after administration of BNT162b2 mRNA vaccine
4 Covid-19: incidence assessed by [ 18 F] FDG PET-CT and relevance for study
5 interpretation: https://pubmed.ncbi.nlm.nih.gov/33774684/
6 807. Lymphadenopathy after COVID-19 vaccination: review of imaging
8 808. Evolution of bilateral hypermetabolic axillary hypermetabolic lymphadenopathy on
9 FDG PET/CT after 2-dose COVID-19
11 809. Lymphadenopathy associated with COVID-19 vaccination on FDG PET/CT:
12 distinguishing features in adenovirus-vectored
14 810. COVID-19 vaccination-induced lymphadenopathy in a specialized breast imaging
15 clinic in Israel: analysis of 163 cases: https://pubmed.ncbi.nlm.nih.gov/34257025/.
16 811. COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: case
17 series with literature review: https://pubmed.ncbi.nlm.nih.gov/34836672/.
18 812. Coronavirus disease vaccine 2019 mimics lymph node metastases in patients
19 undergoing skin cancer follow-up: a single-center
21 813. COVID-19 post-vaccination lymphadenopathy: report of fine-needle aspiration
22 biopsy cytologic findings: https://pubmed.ncbi.nlm.nih.gov/34432391/
23 814. Regional lymphadenopathy after COVID-19 vaccination: review of the literature and
24 considerations for patient management in breast cancer
25 care: https://pubmed.ncbi.nlm.nih.gov/34731748/
26 815. Subclinical axillary lymphadenopathy associated with COVID-19 vaccination on
27 screening mammography: https://pubmed.ncbi.nlm.nih.gov/34906409/
28 816. Adverse events of COVID injection that may occur in children.Acute-onset
29 supraclavicular lymphadenopathy coincident with intramuscular mRNA vaccination
30 against COVID-19 may be related to the injection technique of the vaccine, Spain,
31 January and February 2021: https://pubmed.ncbi.nlm.nih.gov/33706861/
33 follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
34 818. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]
35 choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
36 819. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19
37 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
38 820. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and
39 follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
40 821. A case of cervical lymphadenopathy following COVID-19
42 822. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19
43 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
44 823. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca
45 COVID-19 vaccines: comparison of occurrence and clinical outcomes in the
46 EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/

Page 63
1 824. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management

2 plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
3 825. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-
5 826. A systematic review of cases of CNS demyelination following COVID-19
7 827. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing
8 presentation in the two-week wait neck lump
9 clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
10 828. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with
11 current or previous breast cancer and other malignancies: cross-sectional imaging
12 findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
13 829. Adenopathy after COVID-19
15 830. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-
17 831. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump
18 clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
19 832. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical
20 features and implications for head and neck cancer
21 services: https://pubmed.ncbi.nlm.nih.gov/34526175/
22 833. Lymphadenopathy associated with the COVID-19
24 834. Evolution of lymphadenopathy on PET/MRI after COVID-19
26 835. Autoimmune hepatitis triggered by SARS-CoV-2
28 836. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report
29 and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
30 837. Massive cervical lymphadenopathy following vaccination with COVID-
32 838. ANCA glomerulonephritis following Modern COVID-19
34 839. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19
36 840. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-
37 19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
38 841. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on
39 screening breast MRI allowing benign
40 evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
41 842. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new
42 diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
43 843. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19
45 844. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the
46 USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.

Page 64
1 845. Gastroparesis after Pfizer-BioNTech COVID-19

3 846. Acute-onset supraclavicular lymphadenopathy coincident with intramuscular mRNA
4 vaccination against COVID-19 may be related to the injection technique of the
5 vaccine, Spain, January and February
8 follow-up by ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/
9 848. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]
10 choline PET / CT, not just an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/
11 849. Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19
12 mRNA vaccine COVID-19: https://pubmed.ncbi.nlm.nih.gov/34050949/
13 850. Axillary adenopathy associated with COVID-19 vaccination: imaging findings and
14 follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/
15 851. A case of cervical lymphadenopathy following COVID-19
17 852. Unique imaging findings of neurologic phantosmia after Pfizer-BioNtech COVID-19
18 vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34096896/
19 853. Thrombotic adverse events reported for Moderna, Pfizer, and Oxford-AstraZeneca
20 COVID-19 vaccines: comparison of occurrence and clinical outcomes in the
21 EudraVigilance database: https://pubmed.ncbi.nlm.nih.gov/34835256/
22 854. Unilateral lymphadenopathy after COVID-19 vaccination: a practical management
23 plan for radiologists of all specialties: https://pubmed.ncbi.nlm.nih.gov/33713605/
24 855. Unilateral axillary adenopathy in the setting of COVID-19 vaccination: follow-
26 856. A systematic review of cases of CNS demyelination following COVID-19
28 857. Supraclavicular lymphadenopathy after COVID-19 vaccination: an increasing
29 presentation in the two-week wait neck lump
30 clinic: https://pubmed.ncbi.nlm.nih.gov/33685772/
31 858. COVID-19 vaccine-related axillary and cervical lymphadenopathy in patients with
32 current or previous breast cancer and other malignancies: cross-sectional imaging
33 findings on MRI, CT and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/
34 859. Adenopathy after COVID-19
36 860. Incidence of axillary adenopathy on breast imaging after vaccination with COVID-
38 861. COVID-19 vaccination and lower cervical lymphadenopathy in two-week neck lump
39 clinic: a follow-up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/.
40 862. Cervical lymphadenopathy after coronavirus disease vaccination 2019: clinical
41 features and implications for head and neck cancer
42 services: https://pubmed.ncbi.nlm.nih.gov/34526175/
43 863. Lymphadenopathy associated with the COVID-19
45 864. Evolution of lymphadenopathy on PET/MRI after COVID-19

Page 65
1 865. Autoimmune hepatitis triggered by SARS-CoV-2

3 866. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report
4 and literature review: https://pubmed.ncbi.nlm.nih.gov/34342187/.
5 867. Massive cervical lymphadenopathy following vaccination with COVID-
7 868. ANCA glomerulonephritis following Modern COVID-19
9 869. Extensive longitudinal transverse myelitis following AstraZeneca COVID-19
11 870. Systemic capillary extravasation syndrome after vaccination with ChAdOx1 nCOV-
12 19 (Oxford-AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34362727/
13 871. Unilateral axillary lymphadenopathy related to COVID-19 vaccine: pattern on
14 screening breast MRI allowing benign
15 evaluation: https://pubmed.ncbi.nlm.nih.gov/34325221/
16 872. Axillary lymphadenopathy in patients with recent Covid-19 vaccination: a new
17 diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/.
18 873. Minimal change disease and acute kidney injury after Pfizer-BioNTech COVID-19
20 874. COVID-19 vaccine-induced unilateral axillary adenopathy: follow-up evaluation in the
21 USA: https://pubmed.ncbi.nlm.nih.gov/34655312/.
22 875. Gastroparesis after Pfizer-BioNTech COVID-19
24 876. Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides,
25 S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally
26 associated with BNT162b2 mRNA COVID-19 vaccination in two patients. Int J Cardiol,
27 340, 119-121.
28 doi:10.1016/j.ijcard.2021.08.018. https://www.ncbi.nlm.nih.gov/pubmed/34416319
29 877. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . .
30 Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. Vaccine,
31 39(29), 3790-3793.
32 doi:10.1016/j.vaccine.2021.05.087. https://www.ncbi.nlm.nih.gov/pubmed/34092429
33 878. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis
34 following COVID-19 vaccination. Radiol Case Rep, 16(8), 2142-2145.
35 doi:10.1016/j.radcr.2021.05.033. https://www.ncbi.nlm.nih.gov/pubmed/34025885
36 879. Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W.
37 S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19
38 Vaccination. QJM.
39 doi:10.1093/qjmed/hcab252. https://www.ncbi.nlm.nih.gov/pubmed/34586408
40 880. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal
41 Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. J Emerg Med,
42 61(6), e129-e132.
43 doi:10.1016/j.jemermed.2021.09.017. https://www.ncbi.nlm.nih.gov/pubmed/34756746
44 881. Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., . . .
45 Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a
46 Nationwide Setting. N Engl J Med, 385(12), 1078-1090.
47 doi:10.1056/NEJMoa2110475. https://www.ncbi.nlm.nih.gov/pubmed/34432976
Page 66
1 882. Bhandari, M., Pradhan, A., Vishwakarma, P., & Sethi, R. (2021). Coronavirus and
2 cardiovascular manifestations- getting to the heart of the matter. World J Cardiol,
3 13(10), 556-565.
4 doi:10.4330/wjc.v13.i10.556. https://www.ncbi.nlm.nih.gov/pubmed/34754400
5 883. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA
6 Vaccines. Circulation, 144(6), 471-484.
7 doi:10.1161/CIRCULATIONAHA.121.056135. https://www.ncbi.nlm.nih.gov/pubmed/3
8 4281357
9 884. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021).
10 Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk
11 Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11).
12 doi:10.3390/vaccines9111353. https://www.ncbi.nlm.nih.gov/pubmed/34835284
13 885. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022).
14 Concerning the unexpected prothrombotic state following some coronavirus disease
15 2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74.
16 doi:10.2459/JCM.0000000000001232. https://www.ncbi.nlm.nih.gov/pubmed/3436640
17 3
18 886. Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., &
19 Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about
20 Myocarditis and Pericarditis. Pediatr Rep, 13(3), 530-533.
21 doi:10.3390/pediatric13030061. https://www.ncbi.nlm.nih.gov/pubmed/34564344
22 887. Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M.
23 (2022). Multisystem inflammatory syndrome in a male adolescent after his second
24 Pfizer-BioNTech COVID-19 vaccine. Acta Paediatr, 111(1), 125-127.
25 doi:10.1111/apa.16141. https://www.ncbi.nlm.nih.gov/pubmed/34617315
26 888. Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz,
27 A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19
28 vaccination: just an accidental co-incidence or rather vaccination-associated
29 autoimmune myocarditis? Clin Res Cardiol, 110(11), 1850-1854. doi:10.1007/s00392-
30 021-01916-w. https://www.ncbi.nlm.nih.gov/pubmed/34333695
31 889. Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and
32 Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-
33 Macrothrombosis. Medicina (Kaunas), 57(11).
34 doi:10.3390/medicina57111163. https://www.ncbi.nlm.nih.gov/pubmed/34833382
35 890. Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021).
36 Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in
37 Adolescents. AJR Am J Roentgenol.
38 doi:10.2214/AJR.21.26853. https://www.ncbi.nlm.nih.gov/pubmed/34704459
39 891. Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S.
40 (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19
41 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean
42 Med Sci, 36(40), e286.
43 doi:10.3346/jkms.2021.36.e286. https://www.ncbi.nlm.nih.gov/pubmed/34664804
44 892. Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P.
45 P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19
46 Vaccination at a Global Level. Clin Pharmacol Ther.
47 doi:10.1002/cpt.2499. https://www.ncbi.nlm.nih.gov/pubmed/34860360
Page 67
1 893. Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . .
2 . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong
3 Adolescents Following Comirnaty Vaccination. Clin Infect Dis.
4 doi:10.1093/cid/ciab989. https://www.ncbi.nlm.nih.gov/pubmed/34849657
5 894. Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent
6 myocarditis to differentiate between the acute inflammation and chronic scar? J
7 Pediatr.
8 doi:10.1016/j.jpeds.2021.12.026. https://www.ncbi.nlm.nih.gov/pubmed/34933012
9 895. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . .
10 Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link?
11 Int J Infect Dis, 112, 243-246.
12 doi:10.1016/j.ijid.2021.09.026. https://www.ncbi.nlm.nih.gov/pubmed/34547487
13 896. Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . .
14 Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019
15 Vaccination in Adolescents 12 to 18 Years of Age. J Pediatr, 238, 26-32 e21.
17 897. Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Myocarditis and
18 Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far?
19 Children (Basel), 8(7).
20 doi:10.3390/children8070607. https://www.ncbi.nlm.nih.gov/pubmed/34356586
21 898. Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury
22 Following COVID-19 Vaccination: A Case Report and Review of Current Evidence
23 from Vaccine Adverse Events Reporting System Database. J Prim Care Community
24 Health, 12, 21501327211029230.
25 doi:10.1177/21501327211029230. https://www.ncbi.nlm.nih.gov/pubmed/34219532
26 899. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . .
27 Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-
28 2 Vaccination With mRNA-1279 and BNT162b2. JACC Cardiovasc Imaging, 14(9),
29 1862-1863.
30 doi:10.1016/j.jcmg.2021.06.003. https://www.ncbi.nlm.nih.gov/pubmed/34246585
31 900. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021).
32 Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile
33 idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol.
34 doi:10.1002/art.41977. https://www.ncbi.nlm.nih.gov/pubmed/34492161
35 901. Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021).
36 Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile
37 idiopathic arthritis on treatment with TNF inhibitors. Ann Rheum Dis.
38 doi:10.1136/annrheumdis-2021-
39 221607. https://www.ncbi.nlm.nih.gov/pubmed/34844930
40 902. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., &
41 Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA
42 COVID-19 vaccination in a 40-year-old male: case report. Clin Res Cardiol, 110(11),
43 1855-1859. doi:10.1007/s00392-021-01936-
45 903. El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M.,
46 Anderson, E. J., . . . Group, C. S. (2021). Efficacy of the mRNA-1273 SARS-CoV-2

Page 68
1 Vaccine at Completion of Blinded Phase. N Engl J Med, 385(19), 1774-1785.

3 904. Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute
4 myocarditis in a young adult two days after Pfizer vaccination]. G Ital Cardiol (Rome),
5 22(11), 891-893.
6 doi:10.1714/3689.36746. https://www.ncbi.nlm.nih.gov/pubmed/34709227
7 905. Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M.,
8 Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA
9 COVID-19 vaccines: A systematic review of case reports and case series. Rev Med
10 Virol, e2318. doi:10.1002/rmv.2318. https://www.ncbi.nlm.nih.gov/pubmed/34921468
11 906. Fazolo, T., Lima, K., Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., . . .
12 Bonorino, C. (2021). Pediatric COVID-19 patients in South Brazil show abundant viral
13 mRNA and strong specific anti-viral responses. Nat Commun, 12(1), 6844.
14 doi:10.1038/s41467-021-27120-y. https://www.ncbi.nlm.nih.gov/pubmed/34824230
15 907. Fikenzer, S., & Laufs, U. (2021). Correction to: Response to Letter to the editors
16 referring to Fikenzer, S., Uhe, T., Lavall, D., Rudolph, U., Falz, R., Busse, M., Hepp,
17 P., & Laufs, U. (2020). Effects of surgical and FFP2/N95 face masks on
18 cardiopulmonary exercise capacity. Clinical research in cardiology: official journal of
19 the German Cardiac Society, 1-9. Advance online publication.
20 https://doi.org/10.1007/s00392-020-01704-y. Clin Res Cardiol, 110(8), 1352.
21 doi:10.1007/s00392-021-01896-x. https://www.ncbi.nlm.nih.gov/pubmed/34170372
22 908. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . .
23 Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and
24 Second doses of mRNA COVID-19 Vaccines. Eur Heart J Qual Care Clin Outcomes.
25 doi:10.1093/ehjqcco/qcab090. https://www.ncbi.nlm.nih.gov/pubmed/34849667
26 909. Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., &
27 Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in
28 Immunologically Naive and Pre-Immune Humans. Front Immunol, 12, 728021.
29 doi:10.3389/fimmu.2021.728021. https://www.ncbi.nlm.nih.gov/pubmed/34646267
30 910. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . .
31 Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19
32 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the
33 general population: a multicentre study. Ann Rheum Dis, 80(10), 1330-1338.
34 doi:10.1136/annrheumdis-2021-
36 911. Galindo, R., Chow, H., & Rongkavilit, C. (2021). COVID-19 in Children: Clinical
37 Manifestations and Pharmacologic Interventions Including Vaccine Trials. Pediatr Clin
38 North Am, 68(5), 961-976.
39 doi:10.1016/j.pcl.2021.05.004. https://www.ncbi.nlm.nih.gov/pubmed/34538306
40 912. Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . .
41 Oliver, S. E. (2021). Use of mRNA COVID-19 Vaccine After Reports of Myocarditis
42 Among Vaccine Recipients: Update from the Advisory Committee on Immunization
43 Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep, 70(27), 977-
44 982. doi:10.15585/mmwr.mm7027e2. https://www.ncbi.nlm.nih.gov/pubmed/34237049
45 913. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021).
46 Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint
47 Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse
Page 69
1 Event Reporting System and VigiBase. Vaccines (Basel), 9(1).

2 doi:10.3390/vaccines9010019. https://www.ncbi.nlm.nih.gov/pubmed/33406694
3 914. Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021).
4 A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. Cureus, 13(9),
5 e17890. doi:10.7759/cureus.17890. https://www.ncbi.nlm.nih.gov/pubmed/34660088
6 915. Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. BMJ, 375,
7 n3090. doi:10.1136/bmj.n3090. https://www.ncbi.nlm.nih.gov/pubmed/34916217
8 916. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . .
9 Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and
10 Recommended Evaluation and Management: A Systematic Review, Meta-Analysis,
11 GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol
12 Pract, 9(10), 3546-3567.
13 doi:10.1016/j.jaip.2021.06.006. https://www.ncbi.nlm.nih.gov/pubmed/34153517
14 917. Haaf, P., Kuster, G. M., Mueller, C., Berger, C. T., Monney, P., Burger, P., . . .
15 Tanner, F. C. (2021). The very low risk of myocarditis and pericarditis after mRNA
16 COVID-19 vaccination should not discourage vaccination. Swiss Med Wkly, 151,
17 w30087.
18 doi:10.4414/smw.2021.w30087. https://www.ncbi.nlm.nih.gov/pubmed/34668687
19 918. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu,
20 S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2
21 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord,
22 21(1), 375. doi:10.1186/s12872-021-02183-
24 919. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . .
25 Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years –
26 United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep,
27 70(31), 1053-1058.
28 doi:10.15585/mmwr.mm7031e1. https://www.ncbi.nlm.nih.gov/pubmed/34351881
29 920. Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J.
30 S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia
31 Occurring After SARS-CoV-2 Vaccine. J Blood Med, 12, 221-224.
32 doi:10.2147/JBM.S307047. https://www.ncbi.nlm.nih.gov/pubmed/33854395
33 921. Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . .
34 Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after
35 covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series
36 study. BMJ, 374, n1931.
37 doi:10.1136/bmj.n1931. https://www.ncbi.nlm.nih.gov/pubmed/34446426
38 922. Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K.
39 K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations.
40 Singapore Med J.
41 doi:10.11622/smedj.2021210. https://www.ncbi.nlm.nih.gov/pubmed/34808708
42 923. Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D.
43 (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19
44 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. Drug Saf,
45 44(11), 1209-1214. doi:10.1007/s40264-021-01104-

Page 70
1 924. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines.
2 (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved
3 from https://www.ncbi.nlm.nih.gov/pubmed/34544112https://www.ncbi.nlm.nih.gov/pub
4 med/3454412
5 925. Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise
6 and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination.
7 QJM. doi:10.1093/qjmed/hcab231. https://www.ncbi.nlm.nih.gov/pubmed/34463755
8 926. Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected
9 myocarditis to confirm an acute inflammatory process. QJM.
11 927. Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Myocarditis Following COVID-19
12 Vaccination. Radiology, 301(1), E378-E379.
13 doi:10.1148/radiol.2021211766. https://www.ncbi.nlm.nih.gov/pubmed/34342500
14 928. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin,
15 S., . . . Leuppi-Taegtmeyer, A. B. (2021). Myocarditis and pericarditis in association
16 with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre.
17 Glob Cardiol Sci Pract, 2021(3), e202118.
18 doi:10.21542/gcsp.2021.18. https://www.ncbi.nlm.nih.gov/pubmed/34805376
19 929. Jaafar, R., Boschi, C., Aherfi, S., Bancod, A., Le Bideau, M., Edouard, S., . . . La
20 Scola, B. (2021). High Individual Heterogeneity of Neutralizing Activities against the
21 Original Strain and Nine Different Variants of SARS-CoV-2. Viruses, 13(11).
22 doi:10.3390/v13112177. https://www.ncbi.nlm.nih.gov/pubmed/34834983
23 930. Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . .
24 Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in
25 Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-
27 931. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., .
28 . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of
29 SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10),
30 937-939. doi:10.1093/jpids/piab061. https://www.ncbi.nlm.nih.gov/pubmed/34270752
31 932. Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With
32 Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019
33 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-
35 933. Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . .
36 Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. Int J Cardiol Heart
37 Vasc, 36, 100872.
38 doi:10.1016/j.ijcha.2021.100872. https://www.ncbi.nlm.nih.gov/pubmed/34568540
39 934. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute
40 Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus,
41 13(7), e16590.
42 doi:10.7759/cureus.16590. https://www.ncbi.nlm.nih.gov/pubmed/34447639
43 935. Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S.
44 N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19
45 Vaccination. JAMA Cardiol, 6(10), 1196-1201.
46 doi:10.1001/jamacardio.2021.2828. https://www.ncbi.nlm.nih.gov/pubmed/34185046

Page 71
1 936. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of
2 Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32),
3 e229.
5 937. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., &
6 Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-
7 2, a case series. Am Heart J Plus, 8, 100042.
8 doi:10.1016/j.ahjo.2021.100042. https://www.ncbi.nlm.nih.gov/pubmed/34396358
9 938. Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . .
10 Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA
11 Vaccination. JAMA, 326(14), 1390-1399.
12 doi:10.1001/jama.2021.15072. https://www.ncbi.nlm.nih.gov/pubmed/34477808
13 939. Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., .
14 . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A
15 position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and
16 OGAI. Allergo J Int, 1-17. doi:10.1007/s40629-021-00165-
18 940. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . .
19 Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the
20 Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German
21 Allergy Societies: Medical Association of German Allergologists (AeDA), German
22 Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric
23 Allergology and Environmental Medicine (GPA). Allergo J Int, 30(2), 51-55.
24 doi:10.1007/s40629-020-00160-4. https://www.ncbi.nlm.nih.gov/pubmed/33643776
25 941. Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . .
26 Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in
27 Adolescents: A Survey Study. J Pediatr.
29 942. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P.,
30 Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to “Why are we vaccinating children
31 against COVID-19?” [Toxicol. Rep. 8C (2021) 1665-1684 / 1193]. Toxicol Rep, 8,
32 1981.
33 doi:10.1016/j.toxrep.2021.10.003. https://www.ncbi.nlm.nih.gov/pubmed/34642628
34 943. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P.,
35 Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against
36 COVID-19? Toxicol Rep, 8, 1665-1684.
37 doi:10.1016/j.toxrep.2021.08.010. https://www.ncbi.nlm.nih.gov/pubmed/34540594
38 944. Kremsner, P. G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J. J., . .
39 . Group, C.-N.-S. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle
40 vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien
41 Klin Wochenschr, 133(17-18), 931-941. doi:10.1007/s00508-021-01922-
42 y. https://www.ncbi.nlm.nih.gov/pubmed/34378087
43 945. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A.
44 (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of
45 concern in BNT162b2-mRNA-vaccinated individuals. Nat Med, 27(8), 1379-1384.

Page 72
1 946. Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., .
2 . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. Hong Kong
3 Med J, 27(5), 326-327.
4 doi:10.12809/hkmj215120. https://www.ncbi.nlm.nih.gov/pubmed/34393110
5 947. Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to “Letter to the editor:
6 Myocarditis should be considered in those with a troponin rise and unobstructed
7 coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM.
9 948. Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., .
10 . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2
11 vaccination. Am J Hematol, 96(5), 534-537.
12 doi:10.1002/ajh.26132. https://www.ncbi.nlm.nih.gov/pubmed/33606296
13 949. Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . .
14 Gordon, B. (2021). Myocarditis following COVID-19 vaccination – A case series.
15 Vaccine, 39(42), 6195-6200.
17 950. Li, J., Hui, A., Zhang, X., Yang, Y., Tang, R., Ye, H., . . . Zhu, F. (2021). Safety and
18 immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older
19 Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat
20 Med, 27(6), 1062-1070. doi:10.1038/s41591-021-01330-
22 951. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and
23 Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J
24 Pers Med, 11(11).
25 doi:10.3390/jpm11111106. https://www.ncbi.nlm.nih.gov/pubmed/34834458
26 952. Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E.
27 (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After
28 Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal
29 Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996.
30 doi:10.3389/fcvm.2021.758996. https://www.ncbi.nlm.nih.gov/pubmed/34778411
31 953. Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA
32 COVID-19 Vaccination in Adolescents. J Pediatr, 238, 5.
34 954. Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . .
35 McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA
36 Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-
37 1634.
38 doi:10.1016/j.cjca.2021.08.001. https://www.ncbi.nlm.nih.gov/pubmed/34375696
39 955. Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O.,
40 . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients
41 following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis.
43 956. Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy
44 Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently
45 Positive in an Infant at 6 Months of Age. Case Rep Pediatr, 2021, 6901131.
46 doi:10.1155/2021/6901131. https://www.ncbi.nlm.nih.gov/pubmed/34676123

Page 73
1 957. Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S.
2 (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19
3 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and
4 allergy to PEG-asparaginase. Pediatr Blood Cancer, 68(11), e29295.
5 doi:10.1002/pbc.29295. https://www.ncbi.nlm.nih.gov/pubmed/34398511
6 958. Martins-Filho, P. R., Quintans-Junior, L. J., de Souza Araujo, A. A., Sposato, K. B.,
7 Souza Tavares, C. S., Gurgel, R. Q., . . . Santos, V. S. (2021). Socio-economic
8 inequalities and COVID-19 incidence and mortality in Brazilian children: a nationwide
9 register-based study. Public Health, 190, 4-6.
10 doi:10.1016/j.puhe.2020.11.005. https://www.ncbi.nlm.nih.gov/pubmed/33316478
11 959. McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy
12 adolescent male following COVID-19 vaccination: A case report. Acad Emerg Med,
13 28(8), 918-921.
14 doi:10.1111/acem.14322. https://www.ncbi.nlm.nih.gov/pubmed/34133825
15 960. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-
16 Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in
17 Israel. N Engl J Med, 385(23), 2140-2149.
19 961. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute
20 Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease
21 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323.
23 962. Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., . . . Patalon,
24 T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.
25 Nat Commun, 12(1), 6379. doi:10.1038/s41467-021-26672-
27 963. Moffitt, K., Cheung, E., Yeung, T., Stamoulis, C., & Malley, R. (2021). Analysis of
28 Staphylococcus aureus Transcriptome in Pediatric Soft Tissue Abscesses and
29 Comparison to Murine Infections. Infect Immun, 89(4). doi:10.1128/IAI.00715-
31 964. Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M.
32 G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after
33 vaccination with mRNA-Covid-vaccines: two case reports. BMC Infect Dis, 21(1),
34 1264. doi:10.1186/s12879-021-06949-
36 965. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . .
37 Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19
38 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206.
39 doi:10.1001/jamacardio.2021.2833. https://www.ncbi.nlm.nih.gov/pubmed/34185045
40 966. Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T.
41 (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese
42 Case Series. Intern Med. doi:10.2169/internalmedicine.8731-
44 967. Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . .
45 Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case
46 Report. J Cardiol Cases.
47 doi:10.1016/j.jccase.2021.11.006. https://www.ncbi.nlm.nih.gov/pubmed/34876937
Page 74
1 968. Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P.,
2 Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after
3 acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic
4 Lupus Erythematosus. Clin Immunol, 229, 108765.
5 doi:10.1016/j.clim.2021.108765. https://www.ncbi.nlm.nih.gov/pubmed/34089859
6 969. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . .
7 Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-
8 19 Vaccination in Danish Adolescents. Pediatr Infect Dis J, 41(1), e25-e28.
9 doi:10.1097/INF.0000000000003389. https://www.ncbi.nlm.nih.gov/pubmed/34889875
10 970. Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., . .
11 . Hofmann, M. (2021). Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-
12 2 mRNA vaccine. Nature, 597(7875), 268-273. doi:10.1038/s41586-021-03841-
14 971. Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J.
15 (2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the
16 Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. J
17 Korean Med Sci, 36(32), e232.
19 972. Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting
20 with chest pain and ST segment elevation in adolescents after vaccination with the
21 BNT162b2 mRNA vaccine. Cardiol Young, 1-4.
22 doi:10.1017/S1047951121002547. https://www.ncbi.nlm.nih.gov/pubmed/34180390
23 973. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021).
24 Cardiovascular magnetic resonance findings in young adult patients with acute
25 myocarditis following mRNA COVID-19 vaccination: a case series. J Cardiovasc Magn
26 Reson, 23(1), 101. doi:10.1186/s12968-021-00795-
28 974. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., .
29 . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias
30 associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med.
32 975. Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., &
33 Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy
34 man with previous SARS-CoV-2 infection. Radiol Case Rep, 16(11), 3321-3325.
35 doi:10.1016/j.radcr.2021.07.082. https://www.ncbi.nlm.nih.gov/pubmed/34367386
36 976. Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . .
37 Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series
38 and Incidence Rate Determination. Clin Infect Dis.
40 977. Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . .
41 Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines
42 among healthcare professionals and armed forces with a focus on headache.
43 Panminerva Med, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-
45 978. Pinana, J. L., Lopez-Corral, L., Martino, R., Montoro, J., Vazquez, L., Perez, A., . . .
46 Cell Therapy, G. (2022). SARS-CoV-2-reactive antibody detection after SARS-CoV-2
47 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from
Page 75
1 the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J
2 Hematol, 97(1), 30-42.
3 doi:10.1002/ajh.26385. https://www.ncbi.nlm.nih.gov/pubmed/34695229
4 979. Revon-Riviere, G., Ninove, L., Min, V., Rome, A., Coze, C., Verschuur, A., . . .
5 Andre, N. (2021). The BNT162b2 mRNA COVID-19 vaccine in adolescents and young
6 adults with cancer: A monocentric experience. Eur J Cancer, 154, 30-34.
7 doi:10.1016/j.ejca.2021.06.002. https://www.ncbi.nlm.nih.gov/pubmed/34233234
8 980. Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., &
9 Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial
10 Inflammation: State of the Art Review and Update on Myocarditis Associated with
11 COVID-19 Vaccination. Radiol Cardiothorac Imaging, 3(6), e210252.
12 doi:10.1148/ryct.210252. https://www.ncbi.nlm.nih.gov/pubmed/34934954
13 981. Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa,
14 S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic
15 Acid Coronavirus Disease Vaccine in Adolescents. J Pediatr, 238, 317-320.
17 982. Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., .
18 . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination
19 with COVID-19 vaccines. Int J Legal Med, 135(6), 2335-2345. doi:10.1007/s00414-
20 021-02706-9. https://www.ncbi.nlm.nih.gov/pubmed/34591186
21 983. Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . .
22 . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2
23 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin Res
24 Cardiol, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-
26 984. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C.
27 (2021). Autopsy Findings and Causality Relationship between Death and COVID-19
28 Vaccination: A Systematic Review. J Clin Med, 10(24).
29 doi:10.3390/jcm10245876. https://www.ncbi.nlm.nih.gov/pubmed/34945172
30 985. Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy,
31 Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-
32 Analysis. Front Immunol, 12, 714170.
33 doi:10.3389/fimmu.2021.714170. https://www.ncbi.nlm.nih.gov/pubmed/34707602
34 986. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., . . . Shimabukuro,
35 T. T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19
36 Vaccine – United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18),
37 680-684.
39 987. Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented
40 With Venous Thromboembolism and Disseminated Intravascular Coagulation
41 Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383.
43 988. Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan,
44 A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging
45 study. Eur Heart J Cardiovasc Imaging.
46 doi:10.1093/ehjci/jeab230. https://www.ncbi.nlm.nih.gov/pubmed/34739045

Page 76
1 989. Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S.
2 (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18
3 Years or Older. JAMA Intern Med, 181(12), 1668-1670.
4 doi:10.1001/jamainternmed.2021.5511. https://www.ncbi.nlm.nih.gov/pubmed/346058
5 53
6 990. Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-
7 19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv.
8 doi:10.1101/2021.07.23.21260998. https://www.ncbi.nlm.nih.gov/pubmed/34341797
9 991. Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K.
10 (2021). Deaths in children and young people in England after SARS-CoV-2 infection
11 during the first pandemic year. Nat Med. doi:10.1038/s41591-021-01578-
13 992. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A.,
14 Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving
15 the BNT162b2 mRNA COVID-19 Vaccine. Pediatr Infect Dis J, 40(10), e360-e363.
16 doi:10.1097/INF.0000000000003235. https://www.ncbi.nlm.nih.gov/pubmed/34077949
17 993. Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F.
18 M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in
19 pediatric heart transplantation: A first report. J Heart Lung Transplant.
20 doi:10.1016/j.healun.2021.11.001. https://www.ncbi.nlm.nih.gov/pubmed/34911654
21 994. Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., &
22 Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination.
23 Radiology, 301(2), E409-E411.
24 doi:10.1148/radiol.2021211430. https://www.ncbi.nlm.nih.gov/pubmed/34282971
25 995. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association
26 between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report
27 and literature review. Cardiovasc Revasc Med.
28 doi:10.1016/j.carrev.2021.08.012. https://www.ncbi.nlm.nih.gov/pubmed/34420869
29 996. Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute
30 myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. Eur
31 Heart J Case Rep, 5(8), ytab319.
32 doi:10.1093/ehjcr/ytab319. https://www.ncbi.nlm.nih.gov/pubmed/34514306
33 997. Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021).
34 Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19)
35 Vaccination. Circ J. doi:10.1253/circj.CJ-21-
37 998. Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis
38 After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States,
39 December 14-23, 2020. MMWR Morb Mortal Wkly Rep, 70(2), 46-51.
41 999. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H., Yoon, S. K., Meece, J., .
42 . . Gaglani, M. (2021). Prevention and Attenuation of Covid-19 with the BNT162b2 and
43 mRNA-1273 Vaccines. N Engl J Med, 385(4), 320-329.
45 1000. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . .
46 Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med

Page 77
1 Insights Cardiol, 15, 11795468211056634.

2 doi:10.1177/11795468211056634. https://www.ncbi.nlm.nih.gov/pubmed/34866957
3 1001. Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A.,
4 Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis
5 Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults.
6 Circulation.
7 doi:10.1161/CIRCULATIONAHA.121.056583. https://www.ncbi.nlm.nih.gov/pubmed/3
8 4865500
9 1002. Tutor, A., Unis, G., Ruiz, B., Bolaji, O. A., & Bob-Manuel, T. (2021). Spectrum
10 of Suspected Cardiomyopathy Due to COVID-19: A Case Series. Curr Probl Cardiol,
11 46(10), 100926.
12 doi:10.1016/j.cpcardiol.2021.100926. https://www.ncbi.nlm.nih.gov/pubmed/34311983
13 1003. Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K.
14 (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a
15 male adolescent. CJC Open.
16 doi:10.1016/j.cjco.2021.12.002. https://www.ncbi.nlm.nih.gov/pubmed/34904134
17 1004. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V.
18 A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the
19 mRNA-Based COVID-19 Vaccines. Cureus, 13(6), e15576.
21 1005. Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis
22 Following mRNA COVID-19 Vaccine. Pediatr Emerg Care, 37(11), 583-584.
23 doi:10.1097/PEC.0000000000002557. https://www.ncbi.nlm.nih.gov/pubmed/3473187
24 7
25 1006. Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns,
26 A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to
27 mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health
28 System. JAMA Netw Open, 4(9), e2125524.
29 doi:10.1001/jamanetworkopen.2021.25524. https://www.ncbi.nlm.nih.gov/pubmed/345
30 33570
31 1007. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after
32 BNT162b2 vaccination in a healthy male. Am J Emerg Med, 50, 815 e811-815 e812.
33 doi:10.1016/j.ajem.2021.06.051. https://www.ncbi.nlm.nih.gov/pubmed/34229940
34 1008. Weitzman, E. R., Sherman, A. C., & Levy, O. (2021). SARS-CoV-2 mRNA
35 Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-
36 Private Partnership in a Learning Immunization System. Front Public Health, 9,
37 695807.
38 doi:10.3389/fpubh.2021.695807. https://www.ncbi.nlm.nih.gov/pubmed/34336774
39 1009. Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021).
40 Thrombocytopenia including immune thrombocytopenia after receipt of mRNA
41 COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System
42 (VAERS). Vaccine, 39(25), 3329-3332.
44 1010. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . .
45 Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care
46 Organization. N Engl J Med, 385(23), 2132-2139.
Page 78
1 1011. Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in
2 children? A review of the proposed mechanisms underlying the age-related difference
3 in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136/archdischild-2020-
5 *
6 57 Top Scientists and Doctors Release Shocking Study on COVID Vaccines and
7 Demand Immediate Stop to All Vaccinations
8 Note to readers: Please click the share buttons above or below. Follow us on
9 Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost
10 on your blog site, internet forums. etc.
11 END QUOTE
12
13 As I have exposed in the past I view that the TGA/ATIGA/Department of Health, etc, all
14 blatantly ignored the truth, spread disinformation, etc. In my view the following is to be applied:
15
16 Hansard 1-3-1898 Constitution Convention Debates
17 QUOTE Sir JOHN DOWNER.-
18 I think we might, on the attempt to found this great Commonwealth, just advance one step, not beyond
19 the substance of the legislation, but beyond the form of the legislation, of the different colonies, and say
20 that there shall be embedded in the Constitution the righteous principle that the Ministers of the
21 Crown and their officials shall be liable for any arbitrary act or wrong they may do, in the same way as
22 any private person would be.
23 END QUOTE
24
25 QUOTE Padfield v Minister of Agriculture & Fisheries and Food (1968) AC 997 (1968) 1
26 ALL ER 694 House of Lords - Lord Upjohn and Lord Hodson Upjohn: - (Irrelevant
27 consideration)
28 Here let it be said at once, he and his advisers have obviously given a bona fide and
29 painstaking consideration to the complaints addressed to him; the question is whether the
30 consideration was sufficient in law.
31 END QUOTE
32
33 Scientist and those engaged in health services must accept to be held legally accountable where
34 their so called “professional” advice turns out to be utter and sheer rubbish.
35
36 The same goes for those in the media that if they are willing to participate in a fear campaign
37 then they must be held equally legally accountable as those who committed the crimes against
38 society.
39
40 We need to return to the organics and legal principles embed in of our federal
41 constitution!
42
43 This correspondence is not intended and neither must be perceived to state all issues/details.
44
45 Awaiting your response, G. H. Schorel-Hlavka O.W.B. (Gerrit)
46 MAY JUSTICE ALWAYS PREVAIL®

47 (Our name is our motto!)
48 END QUOTE 20220616-Mr G. H. Schorel-Hlavka O.W.B. to Mr A. Albanese - Mask & vaccine craziness, etc
49
Page 79
1 In my view any person who still recommend the usage of masks as some way to fight an alleged
2 virus simply is “braindead”! Likewise with other absurd mandated! Hold them legally
3 accountable and let them prove that whatever they are spruiking is based upon “science” and
4 indeed is “safe and effective”!
5
6 We must prevent this kind of harmful & murderous conduct to eventuate again by ensuring that
7 those involved in promoting/supporting this kind of conduct are held legally accountable and if
8 convicted are awarded with the death penalty.
9
10 We need to return to the organics and legal principles embed in of our federal
11 constitution!
12
13 This correspondence is not intended and neither must be perceived to state all issues/details.
14 Awaiting your response, G. H. Schorel-Hlavka O.W.B. (Gerrit)
15 MAY JUSTICE ALWAYS PREVAIL®

16 (Our name is our motto!)


20220617-Mr G. H. Schorel-Hlavka O.W.B. To R Kershaw Chief Commissioner of The Australian Federal Police-Suppl 72-Legal Accountability Required

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

20220617-Mr G. H. Schorel-Hlavka O.W.B. To R Kershaw Chief Commissioner of The Australian Federal Police-Suppl 72-Legal Accountability Required

Uploaded by

Copyright:

Available Formats

Page 1

17 2090:53 Jun 08, 2022

17-6-2022 Page 2 © Mr G. H. Schorel-Hlavka O.W.B.

1 WATCH THE FULL EPISODE ON #CHDTV

17-6-2022 Page 3 © Mr G. H. Schorel-Hlavka O.W.B.

17-6-2022 Page 6 © Mr G. H. Schorel-Hlavka O.W.B.

20 Fri, 3 June at 2:03 pm

40 Bring on a Royal Commission and Class Action

17-6-2022 Page 8 © Mr G. H. Schorel-Hlavka O.W.B.

20 The COVID-19 pandemic is one of the most manipulated infectious disease

29 A good example of this outrage against freedom of speech and providing

17-6-2022 Page 11 © Mr G. H. Schorel-Hlavka O.W.B.

1  One Dominant Narrative

6 Click here to read the full document.

38 It’s Now Crucial to Understand What We’re Up Against.

17-6-2022 Page 13 © Mr G. H. Schorel-Hlavka O.W.B.

13 Video: Effort to Stop the Vaccine and Prosecute the

16 Criminal complaint of Gross Negligence Manslaughter and

21 BOMBSHELL: Pfizer’s own documents

20  The scientific priesthood is intolerant to new ideas while, simultaneously, search

17-6-2022 Page 15 © Mr G. H. Schorel-Hlavka O.W.B.

17-6-2022 Page 18 © Mr G. H. Schorel-Hlavka O.W.B.

7  Dr. Parvez Dara, MD, MBA, daraparvez@gmail.com

17-6-2022 Page 19 © Mr G. H. Schorel-Hlavka O.W.B.

3 We can now confirm the 2017 depopulation defence-intelligence documents, showing

10 1. Cerebral venous thrombosis after COVID-19 vaccination in the UK: a multicentre

17-6-2022 Page 20 © Mr G. H. Schorel-Hlavka O.W.B.

1 14. COVID-19 vaccine-induced immune-immune thrombotic thrombocytopenia: an

17-6-2022 Page 21 © Mr G. H. Schorel-Hlavka O.W.B.

17-6-2022 Page 23 © Mr G. H. Schorel-Hlavka O.W.B.

1 65. Myocarditis temporally associated with COVID-19

17-6-2022 Page 24 © Mr G. H. Schorel-Hlavka O.W.B.

17-6-2022 Page 25 © Mr G. H. Schorel-Hlavka O.W.B.

1 103. Cardiac imaging of acute myocarditis after vaccination with COVID-19

17-6-2022 Page 26 © Mr G. H. Schorel-Hlavka O.W.B.

17-6-2022 Page 27 © Mr G. H. Schorel-Hlavka O.W.B.

1 157. COVID-19 mRNA vaccine causing CNS inflammation: a case

1 177. Acute allergic reactions to COVID-19 mRNA

17-6-2022 Page 30 © Mr G. H. Schorel-Hlavka O.W.B.

1 196. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and

17-6-2022 Page 31 © Mr G. H. Schorel-Hlavka O.W.B.

1 214. Thrombosis with thrombocytopenia syndrome (TTS) following AstraZeneca

17-6-2022 Page 32 © Mr G. H. Schorel-Hlavka O.W.B.

1 235. Autoimmune hepatitis triggered by vaccination against SARS-CoV-

17-6-2022 Page 33 © Mr G. H. Schorel-Hlavka O.W.B.

17-6-2022 Page 34 © Mr G. H. Schorel-Hlavka O.W.B.

1 271. Vaccine-induced immune thrombotic thrombocytopenia causing a severe form of

17-6-2022 Page 35 © Mr G. H. Schorel-Hlavka O.W.B.

1 291. Acquired thrombotic thrombocytopenic thrombocytopenic purpura: a rare disease

17-6-2022 Page 36 © Mr G. H. Schorel-Hlavka O.W.B.

1 312. Two cases of Graves’ disease after SARS-CoV-2 vaccination: an autoimmune /

1 333. COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity:

17-6-2022 Page 38 © Mr G. H. Schorel-Hlavka O.W.B.

17-6-2022 Page 39 © Mr G. H. Schorel-Hlavka O.W.B.

17-6-2022 Page 40 © Mr G. H. Schorel-Hlavka O.W.B.

1 388. Cerebral venous sinus thrombosis after vaccination: the UK

17-6-2022 Page 41 © Mr G. H. Schorel-Hlavka O.W.B.

17-6-2022 Page 42 © Mr G. H. Schorel-Hlavka O.W.B.

1 442. Takotsubo (stress) cardiomyopathy after vaccination with ChAdOx1 nCoV-

17-6-2022 Page 44 © Mr G. H. Schorel-Hlavka O.W.B.

1 461. Intracerebral hemorrhage associated with vaccine-induced thrombotic

17-6-2022 Page 45 © Mr G. H. Schorel-Hlavka O.W.B.

1 480. Major hemorrhagic stroke after ChAdOx1 nCoV-19 vaccination: a case